Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(RS)-phenylalanine nitrile + formate
(S)-N-formyl-phenylalanine nitrile
-
-
99% (S)-enantiomer
-
r
2-formyloxycaproylleucyl-p-nitroanilide + H2O
?
-
esterase activity, 10fold lower activity compared to N-formyl-Met-Leu-p-nitroanilide
-
-
?
formyl-L-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
formyl-MAHA + H2O
formate + MAHA
peptide substrate derived from mitochondrial cytochrome c oxidase subunit II
-
-
?
formyl-MEHQ + H2O
formate + MEHQ
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
formyl-Met-Ala-His-Ala + H2O
formate + methionyl-Ala-His-Ala
fMAHA
-
-
?
formyl-Met-Ala-His-Ala-Ala-Gln + H2O
formate + Met-Ala-His-Ala-Ala-Gln
formyl-Met-Ala-Lys + H2O
formate + Met-Ala-Lys
formyl-Met-Ala-Lys-Tyr + H2O
formate + Met-Ala-Lys-Tyr
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
formyl-Met-Gly-Gly-CH3 + H2O
formate + Met-Gly-Gly-CH3
substrate used in QM-MM model
-
-
?
formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
formyl-Met-Lys-Leu + H2O
formate + Met-Lys-Leu
formyl-Met-Pro-Ala + H2O
formate + Met-Pro-Ala
-
-
-
?
formyl-Met-Ser-Asn + H2O
formate + Met-Ser-Asn
formyl-Met-Thr-Gln-Ser-His + H2O
formate + Met-Thr-Gln-Ser-His
formyl-Met-Thr-Met-His + H2O
formate + methionyl-Thr-Met-His
fMTMH
-
-
?
formyl-Met-Thr-Met-His-Thr-Thr + H2O
formate + Met-Thr-Met-His-Thr-Thr
formyl-Met-Thr-Pro-Met-Arg-Lys + H2O
?
-
-
-
-
?
formyl-Met-Thr-Thr + H2O
formate + Met-Thr-Thr
formyl-MFAD + H2O
formate + MFAD
peptide substrate derived from mitochondrial cytochrome c oxidase subunit I
-
-
?
formyl-MFHQ + H2O
formate + MMFQ
-
-
-
?
formyl-MGHQ + H2O
formate + MGHQ
-
-
-
?
formyl-MLHQ + H2O
formate + MLHQ
-
-
-
?
formyl-MLKL + H2O
formate + MLKL
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 4
-
-
?
formyl-MMYA + H2O
formate + MMYA
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 6
-
-
?
formyl-MNFA + H2O
formate + MNFA
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 3
-
-
?
formyl-MNPL + H2O
formate + MNPL
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 2
-
-
?
formyl-MPQL + H2O
formate + MPQL
peptide substrate derived from mitochondrial ATP synthase F0 subunit 8
-
-
?
formyl-MRHQ + H2O
formate + MRHQ
-
-
-
?
formyl-MTHQ + H2O
formate + MTHQ
formyl-MTMH + H2O
formate + MTMH
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 5
-
-
?
formyl-MTPM + H2O
formate + MTPM
peptide substrate derived from mitochondrial cytochrome b
-
-
?
formyl-MVHQ + H2O
formate + MVHQ
-
-
-
?
formylmethionine + H2O
formate + methionine
N-(alpha-difluoroacetyl)-Met-Leu-p-nitroanilide + H2O
difluoroacetic acid + Met-Leu-p-nitroanilide
-
-
-
?
N-(alpha-fluoroacetyl)-Met-Leu-p-nitroanilide + H2O
fluoroacetic acid + Met-Leu-p-nitroanilide
-
-
-
?
N-formyl-1-(1-naphthyl)ethylamine + H2O
(1R)-1-naphthalen-1-ylethanamine + formate
-
-
90% (R)-enantiomer
-
?
N-formyl-3-amino-3-phenylpropionic acid + H2O
(R)-3-amino-3-phenylpropionic acid + formate
-
-
100% (R)-enantiomer
-
?
N-formyl-Ala-Gly-Ser-Glu + H2O
formate + Ala-Gly-Ser-Glu
N-formyl-alaninol + H2O
(S)-alaninol + formate
-
-
85.6% (S)-enantiomer
-
?
N-formyl-alpha-methyl-phenylglycine amide + H2O
(S)-alpha-methyl-phenylglycine amide + formate
-
-
100% (S)-enantiomer
-
?
N-formyl-Asp(NH2) + H2O
?
-
-
-
-
?
N-formyl-beta-thiaphenylalanyl-Ala-Leu-4-nitroanilide + H2O
formate + beta-thiaphenylalanyl-Ala-Leu-4-nitroanilide
-
-
-
-
?
N-formyl-beta-thiaphenylalanyl-Lys-p-nitroanilide + H2O
formate + beta-thiaphenylalanyl-Lys-p-nitroanilide
N-formyl-beta-thiaphenylalanyl-peptide + H2O
formate + beta-thiaphenylalanyl-peptide
N-formyl-beta-thiaphenylalanylleucyl 4-nitroanilide + H2O
formate + beta-thiaphenylalanylleucyl 4-nitroanilide
-
excellent substrate
-
?
N-formyl-Gly(NH2) + H2O
?
-
-
-
-
?
N-formyl-His-Ala-Ser-Arg + H2O
formate + His-Ala-Ser-Arg
-
greatly attenuated activity, preference for N-terminal methionine
-
?
N-formyl-L-Ala-L-Ala-L-Ala + H2O
?
-
-
-
-
?
N-formyl-L-Arg(NH2) + H2O
?
-
-
-
-
?
N-formyl-L-Arg-amide + H2O
?
-
-
-
-
?
N-formyl-L-Met-D-Ala-Ser-Arg + H2O
formate + L-Met-D-Ala-Ser-Arg
-
strong requirement for L-methionine, but D-amino acids tolerated in other positions
-
?
N-formyl-L-Met-L-Ala + H2O
formate + L-Met-L-Ala
-
-
-
-
?
N-formyl-L-Met-L-Ala-L-Ser + H2O
formate + L-Met-L-Ala-L-Ser
N-formyl-L-Met-L-Leu-4-nitroanilide + H2O
formate + L-Met-L-Leu-4-nitroanilide
-
-
-
?
N-formyl-L-Met-L-Lys + H2O
formate + L-Met-L-Lys
-
-
-
-
?
N-formyl-L-Met-L-Val + H2O
formate + L-Met-L-Val
-
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
N-formyl-L-methionine + H2O
formate + L-methionine
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
N-formyl-L-Nle-L-Ala-L-Ser + H2O
formate + L-Nle-L-Ala-L-Ser
-
norleucine is the only excepted substitution for methionine
-
?
N-formyl-Leu(NH2) + H2O
?
-
-
-
-
?
N-formyl-Leu-Tle-NHCH3 + H2O
(S)-Leu-(S)-Tle-NHCH3
-
Tle i.e. tert-leucine
Tle i.e. tert-leucine, 94% (S,S)-diastereomer
-
?
N-formyl-m-methoxyphenylalanine nitrile + H2O
(S)-m-methoxyphenylalanine nitrile + formate
-
-
99% (S)-enantiomer
-
?
N-formyl-Met + H2O
formate + Met
N-formyl-Met-Ala + H2O
formate + Met-Ala
N-formyl-Met-Ala + H2O
Met-Ala + formate
-
-
-
-
?
N-formyl-Met-Ala(OCH3) + H2O
formate + Met-Ala(OCH3)
N-formyl-Met-Ala-Phe-Tyr-beta-Ala-Arg + H2O
formate + Met-Ala-Phe-Tyr-beta-Ala-Arg
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
N-formyl-Met-Leu-Glu + H2O
formate + Met-Leu-Glu
N-formyl-Met-Leu-NH2 + H2O
formate + Met-Leu-NH2
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
N-formyl-Met-Ser-Asn-Glu + H2O
formate + Met-Ser-Asn-Glu
N-formyl-Met-Val-Ser + H2O
formate + Met-Val-Ser
N-formyl-Met-Xaa-Xbb-Tyr + H2O
formate + Met-Xaa-Xbb-Tyr
-
consesus sequence for best substrates, Xaa: any amino acid except for Asp and Glu, Xbb: Lys, Arg, Tyr or Phe
-
?
N-formyl-Nle-Ala(NH2) + H2O
formate + Nle-Ala(NH2)
N-formyl-Nle-Ala-Ser + H2O
formate + Nle-Ala-Ser
N-formyl-Nle-Arg(NH2) + H2O
formate + Nle-Arg(NH2)
N-formyl-Nle-Asn(NH2) + H2O
formate + Nle-Asn(NH2)
-
-
-
-
?
N-formyl-Nle-Asp(NH2) + H2O
formate + Nle-Asp(NH2)
N-formyl-Nle-Gln(NH2) + H2O
formate + Nle-Gln(NH2)
-
-
-
-
?
N-formyl-Nle-Glu(NH2) + H2O
formate + Nle-Glu(NH2)
-
-
-
-
?
N-formyl-Nle-Gly(NH2) + H2O
formate + Nle-Gly(NH2)
N-formyl-Nle-His(NH2) + H2O
formate + Nle-His(NH2)
-
-
-
-
?
N-formyl-Nle-Leu(NH2) + H2O
formate + Nle-Leu(NH2)
N-formyl-Nle-Lys(NH2) + H2O
formate + Nle-Lys(NH2)
-
-
-
-
?
N-formyl-Nle-Met(NH2) + H2O
formate + Nle-Met(NH2)
-
-
-
-
?
N-formyl-Nle-NH(CH3) + H2O
formate + Nle-NH(CH3)
N-formyl-Nle-NH2 + H2O
formate + Nle-Nle-NH2
N-formyl-Nle-Nle(NH2) + H2O
formate + Nle-Nle(NH2)
-
-
-
-
?
N-formyl-Nle-Phe(NH2) + H2O
formate + Nle-Phe(NH2)
-
-
-
-
?
N-formyl-Nle-Pro(NH2) + H2O
formate + Nle-Pro(NH2)
-
-
-
-
?
N-formyl-Nle-Ser(NH2) + H2O
formate + Nle-Ser(NH2)
N-formyl-Nle-Thr(NH2) + H2O
formate + Nle-Thr(NH2)
-
-
-
-
?
N-formyl-Nle-Trp(NH2) + H2O
formate + Nle-Trp(NH2)
-
-
-
-
?
N-formyl-Nle-Tyr(NH2) + H2O
formate + Nle-Tyr(NH2)
-
-
-
-
?
N-formyl-Nle-Val(NH2) + H2O
formate + Nle-Val(NH2)
-
-
-
-
?
N-formyl-Nva-Ala-Ser + H2O
formate + Nva-Ala-Ser
N-formyl-Phe-Ala-Ser + H2O
formate + Phe-Ala-Ser
N-formyl-Phe-Tyr-Phe + H2O
formate + Phe-Tyr-Phe
-
only N-terminal Phe can replace Met
-
?
N-formyl-Phe-Tyr-Phe-His-beta-Ala-Arg + H2O
formate + Phe-Tyr-Phe-His-beta-Ala-Arg
-
-
-
?
N-formyl-Phe-Tyr-Tyr + H2O
formate + Phe-Tyr-Tyr
-
only N-terminal Phe can replace Met
-
?
N-formyl-phenylalanine nitrile + H2O
(S)-phenylalanine nitrile + formate
-
-
98.8% (S)-enantiomer
-
?
N-formyl-phenylglycine + H2O
(S)-phenylglycine + formate
-
-
99.6% (S)-enantiomer
-
?
N-formyl-phenylglycine amide + H2O
(S)-phenylglycine amide + formate
-
-
99.7% (S)-enantiomer
-
?
N-formyl-phenylglycinol + H2O
(S)-phenylglycinol + formate
-
-
90.5-93.3% (S)-enantiomer, depending on method
-
?
N-formyl-Ser(NH2) + H2O
?
-
-
-
-
?
N-formyl-tert-leucine amide + H2O
(S)-tert-leucine amide + formate
-
-
100% (S)-enantiomer
-
?
N-formyl-thiaphenylalanyl-peptide + H2O
formate + thiaphenylalanyl-peptide
-
-
-
-
?
N-formyl-valine nitrile + H2O
(S)-valine nitrile + formate
-
-
98.8% (S)-enantiomer
-
?
N-formylmethionine-alanine + H2O
formate + methionyl-alanine
-
-
-
-
?
N-formylmethionylleucyl-amide + H2O
formate + methionylleucyl-amide
-
-
-
-
?
additional information
?
-
formyl-L-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
formyl-L-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
formyl-L-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
-
peptide deformylase catalyzes the removal of N-terminal formyl groups from nascent ribosome-synthesized polypeptides
-
-
?
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
theoretical study of the catalytic mechanism and metal-ion dependence of peptide deformylase
-
-
?
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
-
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
substrate activity assay
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
substrate activity assay
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
formyl-Met-Ala-His-Ala-Ala-Gln + H2O
formate + Met-Ala-His-Ala-Ala-Gln
-
-
-
-
?
formyl-Met-Ala-His-Ala-Ala-Gln + H2O
formate + Met-Ala-His-Ala-Ala-Gln
-
-
-
-
?
formyl-Met-Ala-Lys + H2O
formate + Met-Ala-Lys
-
-
-
?
formyl-Met-Ala-Lys + H2O
formate + Met-Ala-Lys
-
-
-
?
formyl-Met-Ala-Lys + H2O
formate + Met-Ala-Lys
the substrate is corresponding to the putative N-termini of viral proteins
-
-
?
formyl-Met-Ala-Lys-Tyr + H2O
formate + Met-Ala-Lys-Tyr
-
-
-
-
?
formyl-Met-Ala-Lys-Tyr + H2O
formate + Met-Ala-Lys-Tyr
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
fMAS
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
the substrate is corresponding to the putative capsid N-terminus
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
formyl-Met-Lys-Leu + H2O
formate + Met-Lys-Leu
-
-
-
?
formyl-Met-Lys-Leu + H2O
formate + Met-Lys-Leu
-
-
-
?
formyl-Met-Lys-Leu + H2O
formate + Met-Lys-Leu
the substrate is corresponding to the putative N-termini of viral proteins
-
-
?
formyl-Met-Ser-Asn + H2O
formate + Met-Ser-Asn
-
-
-
?
formyl-Met-Ser-Asn + H2O
formate + Met-Ser-Asn
-
-
-
?
formyl-Met-Ser-Asn + H2O
formate + Met-Ser-Asn
the substrate is corresponding to the putative helicase N-terminus
-
-
?
formyl-Met-Thr-Gln-Ser-His + H2O
formate + Met-Thr-Gln-Ser-His
-
-
-
-
?
formyl-Met-Thr-Gln-Ser-His + H2O
formate + Met-Thr-Gln-Ser-His
-
-
-
-
?
formyl-Met-Thr-Met-His-Thr-Thr + H2O
formate + Met-Thr-Met-His-Thr-Thr
-
-
-
-
?
formyl-Met-Thr-Met-His-Thr-Thr + H2O
formate + Met-Thr-Met-His-Thr-Thr
-
-
-
-
?
formyl-Met-Thr-Thr + H2O
formate + Met-Thr-Thr
-
-
-
?
formyl-Met-Thr-Thr + H2O
formate + Met-Thr-Thr
-
-
-
?
formyl-Met-Thr-Thr + H2O
formate + Met-Thr-Thr
the substrate is corresponding to the putative N-termini of viral proteins
-
-
?
formyl-MTHQ + H2O
formate + MTHQ
-
-
-
?
formyl-MTHQ + H2O
formate + MTHQ
peptide substrate derived from mitochondrial cytochrome c oxidase subunit III
-
-
?
formylmethionine + H2O
formate + methionine
the smallest efficient substrate of PDF
-
-
?
formylmethionine + H2O
formate + methionine
the smallest efficient substrate of PDF
-
-
?
formylmethionine + H2O
formate + methionine
the smallest efficient substrate of PDF
-
-
?
formylmethionine + H2O
formate + methionine
the smallest efficient substrate of PDF
-
-
?
N-formyl-Ala-Gly-Ser-Glu + H2O
formate + Ala-Gly-Ser-Glu
-
poor activity, preference of N-terminal methionine
-
?
N-formyl-Ala-Gly-Ser-Glu + H2O
formate + Ala-Gly-Ser-Glu
-
poor activity, preference of N-terminal methionine
-
?
N-formyl-beta-thiaphenylalanyl-Lys-p-nitroanilide + H2O
formate + beta-thiaphenylalanyl-Lys-p-nitroanilide
-
-
-
?
N-formyl-beta-thiaphenylalanyl-Lys-p-nitroanilide + H2O
formate + beta-thiaphenylalanyl-Lys-p-nitroanilide
-
-
-
?
N-formyl-beta-thiaphenylalanyl-peptide + H2O
formate + beta-thiaphenylalanyl-peptide
-
-
-
?
N-formyl-beta-thiaphenylalanyl-peptide + H2O
formate + beta-thiaphenylalanyl-peptide
-
significantly poorer substrate than N-formyl-thiaphenylalanylleucyl-p-nitroanilide
-
?
N-formyl-L-Met-L-Ala-L-Ser + H2O
formate + L-Met-L-Ala-L-Ser
activity assay
-
-
?
N-formyl-L-Met-L-Ala-L-Ser + H2O
formate + L-Met-L-Ala-L-Ser
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
-
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
-
-
-
-
?
N-formyl-L-methionine + H2O
formate + L-methionine
-
worst substrate
-
-
?
N-formyl-L-methionine + H2O
formate + L-methionine
-
worst substrate
-
-
?
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
-
-
-
?
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
essential role in protein processing in plastids
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
deformylase is likely to play an essential role in the chloroplast
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
deformylation required for methionine aminopeptidase activity in eubacteria, highly specific
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
requires at least a dipeptide as substrate, increasing activity with increasing peptide length until it reaches the tetrapeptide
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
deformylation required for methionine aminopeptidase activity in eubacteria, highly specific
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
the enzyme is involved in maturation of proteins by cleaving the N-formyl group from N-blocked methionine polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
the enzyme is requiredfor the removal of the formyl group at the N-terminus of nascent polypeptide chains
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
posttranslational deformylation of N-formyl-Met-polypeptide
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
deformylation required for methionine aminopeptidase activity in eubacteria, highly specific
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
deformylation required for methionine aminopeptidase activity in eubacteria, highly specific
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
involved in polypeptide synthesis by removal of the formyl-group from methionine in growing polypeptides
-
-
?
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
-
-
-
?
N-formyl-Met + H2O
formate + Met
-
-
-
?
N-formyl-Met + H2O
formate + Met
-
poor activity
-
?
N-formyl-Met + H2O
formate + Met
-
poor activity
-
?
N-formyl-Met + H2O
formate + Met
-
minimal substrate
-
?
N-formyl-Met + H2O
formate + Met
-
minimal substrate
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala + H2O
formate + Met-Ala
-
-
-
?
N-formyl-Met-Ala(OCH3) + H2O
formate + Met-Ala(OCH3)
-
-
-
-
?
N-formyl-Met-Ala(OCH3) + H2O
formate + Met-Ala(OCH3)
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
higher activity than compared to di- or tetrapeptides
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
best substrate
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
best substrate
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
-
-
-
-
?
N-formyl-Met-Leu-Glu + H2O
formate + Met-Leu-Glu
-
-
-
-
?
N-formyl-Met-Leu-Glu + H2O
formate + Met-Leu-Glu
-
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
best substrate
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
-
best substrate
-
?
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
-
-
-
-
?
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
-
-
-
-
?
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
-
-
-
-
?
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
-
-
-
-
?
N-formyl-Met-Ser-Asn-Glu + H2O
formate + Met-Ser-Asn-Glu
-
-
-
-
?
N-formyl-Met-Ser-Asn-Glu + H2O
formate + Met-Ser-Asn-Glu
-
-
-
-
?
N-formyl-Met-Ser-Asn-Glu + H2O
formate + Met-Ser-Asn-Glu
-
decreasing activity for tetrapeptides
-
?
N-formyl-Met-Val-Ser + H2O
formate + Met-Val-Ser
-
-
-
-
?
N-formyl-Met-Val-Ser + H2O
formate + Met-Val-Ser
-
-
-
-
?
N-formyl-Nle-Ala(NH2) + H2O
formate + Nle-Ala(NH2)
-
-
-
-
?
N-formyl-Nle-Ala(NH2) + H2O
formate + Nle-Ala(NH2)
-
-
-
-
?
N-formyl-Nle-Ala-Ser + H2O
formate + Nle-Ala-Ser
-
-
-
-
?
N-formyl-Nle-Ala-Ser + H2O
formate + Nle-Ala-Ser
-
-
-
-
?
N-formyl-Nle-Arg(NH2) + H2O
formate + Nle-Arg(NH2)
-
-
-
-
?
N-formyl-Nle-Arg(NH2) + H2O
formate + Nle-Arg(NH2)
-
-
-
-
?
N-formyl-Nle-Asp(NH2) + H2O
formate + Nle-Asp(NH2)
-
-
-
-
?
N-formyl-Nle-Asp(NH2) + H2O
formate + Nle-Asp(NH2)
-
-
-
-
?
N-formyl-Nle-Gly(NH2) + H2O
formate + Nle-Gly(NH2)
-
-
-
-
?
N-formyl-Nle-Gly(NH2) + H2O
formate + Nle-Gly(NH2)
-
-
-
-
?
N-formyl-Nle-Leu(NH2) + H2O
formate + Nle-Leu(NH2)
-
-
-
-
?
N-formyl-Nle-Leu(NH2) + H2O
formate + Nle-Leu(NH2)
-
-
-
-
?
N-formyl-Nle-NH(CH3) + H2O
formate + Nle-NH(CH3)
-
-
-
-
?
N-formyl-Nle-NH(CH3) + H2O
formate + Nle-NH(CH3)
-
-
-
-
?
N-formyl-Nle-NH2 + H2O
formate + Nle-Nle-NH2
-
-
-
-
?
N-formyl-Nle-NH2 + H2O
formate + Nle-Nle-NH2
-
-
-
-
?
N-formyl-Nle-Ser(NH2) + H2O
formate + Nle-Ser(NH2)
-
-
-
-
?
N-formyl-Nle-Ser(NH2) + H2O
formate + Nle-Ser(NH2)
-
-
-
-
?
N-formyl-Nva-Ala-Ser + H2O
formate + Nva-Ala-Ser
-
-
-
-
?
N-formyl-Nva-Ala-Ser + H2O
formate + Nva-Ala-Ser
-
-
-
-
?
N-formyl-Phe-Ala-Ser + H2O
formate + Phe-Ala-Ser
-
-
-
-
?
N-formyl-Phe-Ala-Ser + H2O
formate + Phe-Ala-Ser
-
-
-
-
?
additional information
?
-
coupled enzyme activity assay with formate dehydrogenase
-
-
-
additional information
?
-
-
overview
-
-
?
additional information
?
-
-
proposed reaction cycle of peptide deformylase
-
-
?
additional information
?
-
catalyzes the deformylation of nascent peptides in bacteria
-
-
?
additional information
?
-
-
catalyzes the deformylation of nascent peptides in bacteria
-
-
?
additional information
?
-
the removal of the formyl group from formylated methionine residues is facilitated by the action of peptide deformylase
-
-
?
additional information
?
-
-
the removal of the formyl group from formylated methionine residues is facilitated by the action of peptide deformylase
-
-
?
additional information
?
-
comparison of substrate specificity of the Escherichia coli PDF Vibrio phage Vp16 PDF
-
-
-
additional information
?
-
coupled enzyme activity assay with formate dehydrogenase
-
-
-
additional information
?
-
the formyl moiety of newly synthesized peptides is removed by peptide deformylase
-
-
?
additional information
?
-
-
the formyl moiety of newly synthesized peptides is removed by peptide deformylase
-
-
?
additional information
?
-
-
no activity with formyl-Met-Thr-Pro-Met-Arg-Lys
-
-
?
additional information
?
-
-
no detectable activity with formyl-Met-Leu-Phe and formyl-Met-Leu-Pro
-
-
?
additional information
?
-
HsPDF can process, in vitro, N-Met-formylated peptides
-
-
?
additional information
?
-
-
HsPDF can process, in vitro, N-Met-formylated peptides
-
-
?
additional information
?
-
catalyzes the removal of the N-formyl group from the N-terminus of newly synthesized proteins
-
-
?
additional information
?
-
-
catalyzes the removal of the N-formyl group from the N-terminus of newly synthesized proteins
-
-
?
additional information
?
-
-
peptide deformylase is involved in the deformylation of the N-formyl group of newly synthesized polypeptides during protein synthesis
-
-
?
additional information
?
-
-
peptide deformylase is involved in the deformylation of the N-formyl group of newly synthesized polypeptides during protein synthesis
-
-
?
additional information
?
-
catalyzes the removal of the N-formyl group from the N-terminus of newly synthesized proteins
-
-
?
additional information
?
-
the formyl group is removed from nascent proteins by peptide deformylase
-
-
?
additional information
?
-
the formyl group is removed from nascent proteins by peptide deformylase
-
-
?
additional information
?
-
-
the formyl group is removed from nascent proteins by peptide deformylase
-
-
?
additional information
?
-
-
peptide deformylase is responsible for the removal of the N-formyl group from the terminal methionine residue in bacterial protein synthesis
-
-
?
additional information
?
-
Staphylococcus enteridis
-
peptide deformylase is responsible for the removal of the N-formyl group from the terminal methionine residue in bacterial protein synthesis
-
-
?
additional information
?
-
-
peptide deformylase is responsible for the removal of the N-formyl group from the terminal methionine residue in bacterial protein synthesis
-
-
?
additional information
?
-
isoform PDF-2 exhibits no peptide deformylase activity
-
-
?
additional information
?
-
isoform PDF-2 exhibits no peptide deformylase activity
-
-
?
additional information
?
-
-
isoform PDF-2 exhibits no peptide deformylase activity
-
-
?
additional information
?
-
Staphylococcus non-hemolyticus
-
peptide deformylase is responsible for the removal of the N-formyl group from the terminal methionine residue in bacterial protein synthesis
-
-
?
additional information
?
-
coupled enzyme activity assay with formate dehydrogenase
-
-
-
additional information
?
-
-
coupled enzyme activity assay with formate dehydrogenase
-
-
-
additional information
?
-
coupled enzyme activity assay with formate dehydrogenase
-
-
-
additional information
?
-
-
peptide deformylase is responsible for the removal of the N-formyl group from the terminal methionine residue in bacterial protein synthesis
-
-
?
additional information
?
-
the enzyme deformylates the N-terminal tetrapeptides from D1 proteins more efficiently than those from ribosomal proteins
-
-
?
additional information
?
-
-
TbPDF1 is essential for normal growth. TbPDF1 is required for oxidative but not for mitochondrial substrate-level phosphorylation
-
-
?
additional information
?
-
-
TbPDF2 does neither affect growth on standard medium nor oxidative phosphorylation. A reduced level of TbPDF2 slows down growth in a medium that selects for highly efficient oxidative phosphorylation
-
-
?
additional information
?
-
Vp16 PDF shows high catalytic efficiency in vitro and with substrate specificity comparable to other PDFs, comparison to the Escherichia coli PDF
-
-
-
additional information
?
-
-
catalyzes the removal of the N-formyl group from the N-terminus of newly synthesized polypeptides
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-hydroxyaminomethyl-2-phenylethyl)carbamic acid tert-butyl ester
AtPDF2
(1-hydroxycarbamoylmethyl-2-phenylethyl)carbamic acid tert-butyl ester
AtPDF2
(2E)-3-(2,5-dihydroxyphenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
-
(2R)-2-(2-cyclopentylethyl)-N4-hydroxy-N1-[(2S)-1-[(2R)-2-hydroxypyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]butanediamide
-
(2R)-2-[(N-hydroxyformamido)methyl]hexanoic acid
the proteolyzed fragment is bound to the active site
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N-[(1S)-5-amino-1-(hexylcarbamoyl)pentyl]-2-[[formyl(hydroxy)amino]methyl]heptanamide
-
(2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
an actinonin derivative
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
(2R)-N-[(3S)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4,4-dimethylpent-1-en-3-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N-[6-carbamimidamido-1-(naphthalen-2-yl)-2-oxohexan-3-yl]-2-(sulfanylmethyl)hexanamide
-
(2R)-N4-hydroxy-N1-[(2R)-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
-
(2R)-N4-hydroxy-N1-[(2S)-3-methyl-1-oxo-1-(piperidin-1-yl)butan-2-yl]-2-pentylbutanediamide
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-4H-pyrazol-3-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-{(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl}-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]pent-4-ynoic acid
-
(2S)-6-amino-2-[(2S)-2-[(hydroxyamino) methyl]hexanamido]-N-phenylhexanamide
the acid hydrolyzed fragment, which exists as a dimer, is characterized as an intersubunit molecule
(2S)-6-amino-2-[(2S)-2-[(N-hydroxyformamido)methyl]hexanamido]-N-phenyl hexanamide
-
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N1-(2-cyclopentylethyl)-N2-(4,5-dimethyl-1,3-thiazol-2-yl)-N1-[2-(hydroxyamino)-2-oxoethyl]pyrrolidine-1,2-dicarboxamide
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3R,4S,5R,6R)-2-[(5-bromo-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,3R,4S,5S,6R)-2-[(5-bromo-6-chloro-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2Z)-2-(3-butyl-1,3-benzothiazol-2(3H)-ylidene)-N-hydroxyacetamide
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
(4S)-N-[3-chloro-2-(morpholin-4-yl)phenyl]-3-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-1,3-oxazolidine-4-carboxamide
active against Staphylococcus aureus and Streptomyces strains
(5Z)-5-([2-[(E)-2-(dimethylamino)ethenesulfonyl]-6-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene)-1,3-thiazolidine-2,4-dione
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(1H-pyrazol-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-[(pyrimidin-2-yl)amino]phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(pyridin-3-yl)pyrimidin-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(1H-benzimidazol-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(3-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(4-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(5-tert-butyl-1,2-oxazol-3-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(E)-1,5-dimethyl-2-phenyl-4-((5-styryl-1,3,4-thiadiazol-2-yl)amino-1,2-dihydro-3H-pyrazole-3-one)
-
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,4-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,5-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,6-dichlorobenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2-chlorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4,5-trimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-chlorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-fluorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-methoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-benzylidenethiazolidine-2,4-dione
-
(E)-5-methyl-N-(5-styryl-1,3,4-thiadiazole-2-yl)isoxazol-3-amine
-
-
(E)-5-styryl-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
-
-
(E)-N-(furan-2-ylmethyl)-5-styryl-1,3,4-thiadiazol-2-amine
-
-
(E)-N-phenethyl-3-(3,4-diacetoxyphenyl)acrylamide
IC50: 0.00125 mM
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid ((S)-5-amino-1-phenylcarbamoyl-pentyl)-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((R)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((S)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(RS)- and (SR)-3-[(RS)-benzenesulfinyl]heptanoic acid hydroxyamide
-
mixture of both components, IC50: 0.0001 mM, possible antimicrobial agent
(RS)-3-(phenylsulfonyl)heptanoic acid hydroxyamide
-
IC50: 0.035 micro molar, possible antimicrobial agent
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-2-O-(H-phosphonoxy)-L-caproyl-L-Leu-p-nitroanilide
-
similar inhibition of Fe2+- and Co2+-bound enzyme
(S)-2-O-(phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(Z)-4-hydroxy-3-(5-((4-(phenyldiazenyl) phenyl) amino)-1,3,4-thiadiazol-2-yl)benzene sulfonic acid
-
-
(Z)-5-(3,4-dimethoxyphenyl)-N-(4-(phenyl diazenyl) phenyl)-1,3,4-thiadiazol-2-amine
-
-
(Z)-N-(4-methylpyridine-2-yl)-5-styryl-1,3,4-thiadiazol-2-amine
-
-
1,2-Ethanedithiol
-
irreversible
1,3-propanedithiol
-
irreversible
1-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(5-bromo-1H-indol-3-yl)-3-hydroxypropan-2-one
AtPDF2
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
1-(methylamino)-3-[2-(prop-2-en-1-yl)phenoxy]propan-2-ol
-
1-[(2-methoxyphenyl)carbamoyl]prolyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-methylidene-N-(5-methyl-1,3-thiazol-2-yl)-L-prolinamide
active against Staphylococcus aureus strains
1-[(2R)-2-[(2S)-1-(hydroxyamino)-1-oxopropan-2-yl]hexanoyl]-N-propyl-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
2',2'-bisepigallocatechin monogallate
-
-
2,3-dichloro-N-[2-[formyl(hydroxy)amino]ethyl]benzamide
active against Haemophilus influenzae strains
2,3-dimercapto-1-propanesulfonic acid
-
-
2,3-dimercapto-1-propanol
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(1-benzyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.002 mM
2-(1-butyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00059 mM
2-(2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00076 mM
2-(2,2-dioxo-1,4-dihydro-2lambda6,1,3-benzothiadiazin-3(2H)-yl)-N-hydroxyacetamide
2-(2-ethoxy-4-(((4-(3-oxomorpholino)phenyl)amino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0364, 0.120, and 0.0480 mM, respectively
2-(2-ethoxy-4-((morpholinoamino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0096, 0.0679, and 0.0229 mM, respectively
2-(2-ethoxy-4-((pyridin-3-ylamino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0966, 0.0454, and 0.0136 mM, respectively
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
2-(4-benzyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(4-formyl-3,5-diiodophenyl)-N-hydroxyacetamide
-
2-(4-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(5-bromo-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000069 mM
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000098 mM
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2-methyl-1H-indolyl)-N-hydroxyacetamide
2-(5-bromo-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.000049 mM
2-(5-chloro-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00011 mM
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00012 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00031 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide
-
IC50: 0.027 mM
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-fluoro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-fluoro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-methoxy-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(biphenyl-4-yl)-N-oxoacetamide
-
2-(indol-3-yl)-N-hydroxyacetamide
2-amino-5-mercapto-1,3,4-thiadiazole
slow-binding inhibitor of PDF when dissolved only in dimethylformamide, but not in any other solvent, and aged (via the formation of a disulfide bond) to a dimeric form
2-amino-N-[(1S,2S)-1-hydroxy-1-phenylpropan-2-yl]-N-methylacetamide
-
2-amino-N-[4-(2,5-dimethoxyphenyl)butyl]ethane-1-sulfonamide
CAP05909402, docking into PfPDF-Co2+-actinonin complex
2-butyl-5,7-dimethyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a class of angiotensin II receptor antagonists, potent inhibitor, IC50: 0.0076 mM
2-hydroxy-4-phenoxybutanal
active against Haemophilus influenzae strains
2-mercaptoethanol
-
30% inhibition at 1 mM
2-oxo-pyrrolidine with chelators
-
-
-
2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
CAPE, does not chelate HpPDF and does not disrupt the metal-dependent catalysis
2-thioxo-4-thiazolidinone N-hexanoic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00166 mM
2-thioxo-4-thiazolidinones
-
-
-
2-[(12R,17aS)-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecin-12-yl]-N-hydroxyacetamide
-
-
2-[(3-aminopropanoyl)amino]-3-phenylpropanoic acid
-
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
2-[2,2-dioxido-5-(trifluoromethyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00013 mM
2-[2-chloro-4-([[2-(1H-indol-3-yl)ethyl]amino]methyl)-6-methoxyphenoxy]acetamide
i.e. M7594_0037, the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0353, 0.0296, and 0.0246 mM, respectively
2-[2-[(2-hydroxyethyl)amino]-1H-benzimidazol-1-yl]-1-phenylethanone
-
2-[4-(3,3-dimethyl-2-oxobutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(3-methylbutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[5-chloro-2,2-dioxido-1-(3-phenylpropyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00029 mM
2-[[formyl(hydroxy)amino]methyl]-N-[(5-methoxy-1H-benzimidazol-2-yl)methyl]hexanamide
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
3-(3-acetylsulfanyl-2-oxopropyl)indole-1-carboxylic acid benzyl ester
AtPDF2
3-(5-((4H-1,2,4-triazol-4-yl)amino)-1,3,4-thiadiazol-2-yl)-4-hydroxy benzenesulfonic acid
-
-
3-(5-((furan-2-ylmethyl)amino)-1,3,4-thiadiazole-2-yl)-4-hydroxybenzenesulfonic acid
-
-
3-(5-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]-4H-1,2,4-triazol-3-yl)-4-hydroxybenzenesulfonic acid
-
-
3-carboxymethylindol-1-carboxylic acid benzyl ester
AtPDF2
3-methoxy-7-methyl-1,3-dihydro-2-benzofuran-4,5,6-triol
has antibacterial activity on Staphylococcus aureus strains
3-methyl-N-(1,3-thiazol-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(2-methylpropanoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(morpholin-4-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(phenylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(piperidin-1-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-3-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-4-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(thiophen-2-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-[methyl(phenyl)carbamoyl]-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-[5'-benzyl-2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
-
potent inhibitor, IC50: 0.0342 mM, the acidic moiety forms direct ionic interactions with active site metal cation
4'-((2-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-fluoro-4-morpholinophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-carboxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-chloro-2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4H-1,2,4-triazol-4-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-((6-methoxybenzothiazol-2-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-((phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((pyrazin-2-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-(2-ethyl-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl)[1,1'-biphenyl]-2-carboxylic acid
-
4'-([(5Z)-2,4-dioxo-5-[(3,4,5-trimethoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,4-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,5-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,6-dichlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2-chlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-chlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-fluorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-methoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-[(2-ethyl-6,8-dimethyl-3,5-dihydroimidazo[1,2-b]pyridazin-3-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
-
4'-[[(5Z)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]methyl][1,1'-biphenyl]-2-carbonitrile
-
4-((5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazol-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
-
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
4-amino-3-[[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl]sulfanyl]-6-methyl-1,2,4-triazin-5(4H)-one
CAP01891052, docking into PfPDF-Co2+-actinonin complex
4-hydroxy-3-(5-((5-methylisoxazol-3-yl)amino)-1,3,4-thiadiazol-2-yl)benzenesulfonic acid
-
-
4-hydroxy-3-(5-[(4-methylpyridin-2-yl)amino]-4H-1,2,4-triazol-3-yl)benzenesulfonic acid
-
-
4-methyl-1,3-dihydro-2-benzofuran-1,5,6,7-tetrol
has antibacterial activity on Staphylococcus aureus strains
4-[(Z)-[3-(2-chlorobenzoyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-N-(4-phenyl-1,3-thiazol-2-yl)benzene-1-sulfonamide
-
5'-phosphothiorate modified antisense oligodeoxyribonucleotides
-
-
-
5,5'-disulfanediyldi(1,3,4-thiadiazol-2-amine)
dimerization of two 2-amino-5-mercapto-1,3,4-thiadiazole molecules via the dithiol linkage forming bis-AMT
5-(3,4-dimethoxyphenyl)-N-(4-methylpyridine-2-yl)-1,3,4-thiadiazol-2-amine
-
-
5-(3,4-dimethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
-
-
5-(3,4-dimethoxyphenyl)-N-(furan-2-ylmethyl)-1,3,4-thiadiazol-2-amine
-
-
5-([[(1-benzothiophen-2-yl)methyl]sulfanyl]methyl)-N-hydroxy-1,2-oxazole-3-carboxamide
poor antibacterial activity
5-amino-1,3,4-thiadiazole-2-thiol
a slow-binding inhibitor of Escherichia coli Ni-PDF inhibitor upon aging
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
5-bromo-7-methyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine
-
5-chloro-2-propyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a broad class of angiotensin II receptor antagonists, potent competitive inhibitor, IC50: 0.0039 mM, the acidic moiety forms direct ionic interactions with active site metal cation
5-chloro-2-propyl-3-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-3H-imidazo[4,5-b]pyridine
-
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
5-[[(2-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3,4-dichlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3-chlorophenyl)sulfonyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
5-[[(4-methoxyphenyl)sulfonyl]methyl]-1,2-oxazole-3-carbohydrazide
-
6,7-dibromo-3-(3,4-dimethoxy-5-methylbenzoyl)-1-benzofuran-4(5H)-one
-
6,7-dichloro-3-(3,4-dimethoxybenzoyl)-1-benzofuran-4,5-dione
-
6-chloro-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole
8-hydroxyquinoline
-
50% inhibition at 2 mM
aldehyde peptide
-
IC50 against Escherichia coli peptide deformylase: 0.01 mM
-
alkyl-succinate-proline hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000004-0.000010 mM
analogues of actinonin
-
35 different compounds were synthesized and compared to the inhibitory activity of actinonin
-
benzimidazole N-formyl hydroxylamine
-
-
benzothiazinone derivatives
-
IC50: 0.000005 mM
-
benzothiazolylidene hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.00104 mM
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
beta-sulfonylhydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.000016 mM
butyl {[4'-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)-5-(2-methylbutan-2-yl)biphenyl-2-yl]sulfonyl}carbamate
-
competitive inhibition, IC50: 0.015 mM, the acidic moiety forms direct ionic interactions with active site metal cation
caffeic acid phenethyl ester
-
CAPE, an active component of propolis, 75% inhibition at 0.01 mM, the competitive inhibitor blocks the substrate entrance, preventing substrate from approaching the active site, but CAPE does not have chelate interaction with HpPDF and does not disrupt the metal-dependent catalysis
carbamate N-formyl hydroxylamine
-
-
Co(III)1
-
peptide cleaving catalyst
cryptochlorogenic acid
with high score in enzyme docking analysis
Diethylenetriaminepentaacetic acid
dihydromyricetin
with high score in enzyme docking analysis
diprop-2-en-1-yl (2S)-2-aminobutanedioate
-
drechmerin I
an antibacterial compound, isolated from the fermentation broth of Drechmeria sp. strain SYPF 8335, which is isolated from the inside root of Panax notoginseng, from Wenshan district, Yunnan province of China. Compound structure determination by mass spectrometry and 1H and 13C NMR. Molecular docking in the active site of PDF from Staphylococcus aureus through the hydrogen bonds with Try88 and Arg143. Drechmerin I displays antimicrobial activity against Bacillus subtillis with an MIC value of 0.2 mg/ml
epigallocatechin 3,5-digallate
-
-
epitheaflavin monogallate
-
-
ethyl 1-(N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]heptanoyl]-L-valyl)piperidine-3-carboxylate
-
ethyl 2-(2-ethoxy-4-(((4-(3-oxomorpholino)phenyl)amino)methyl)phenoxy)acetate
-
ethyl 2-(2-ethoxy-4-((morpholinoamino)methyl)phenoxy)acetate
-
ethyl 2-(2-ethoxy-4-formylphenoxy)acetate
-
ethyl 2-amino-3-(benzylsulfanyl)propanoate
-
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
-
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
Fe3+
-
inactivation due to oxidation of Fe2+ to Fe3+
flavimycin A
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
flavimycin B
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
gentiopicroside
with high score in enzyme docking analysis
glutathione
-
10% inhibition at 1 mM
heteroarylaryl(P2'/P3')N-formyl hydroxylamine
-
-
hydantoin
-
IC50 against Escherichia coli peptide deformylase: 0.0002 mM
hydrazide N-formyl hydroxylamine
-
-
imino[(5-methoxy-5-oxo-4-[2-(sulfanylmethyl)hexanoyl]aminopentyl)amino]methaneamine
isoxazole-3-hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.0034 mM
-
isoxazole-3-hydroxamic acids
-
methyl (3R)-3-[2-(4-carbamoylpiperidin-1-yl)acetamido]-4-chloro-3H-indole-2-carboxylate
IBS297042, docking into PfPDF-Co2+-actinonin complex
methyl 3-[(8-methyl-2,3-dihydrofuro[3,2-e]imidazo[1,2-c]pyrimidine-9-carbonyl)amino]thiophene-2-carboxylate
CD1691700, docking into PfPDF-Co2+-actinonin complex
methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
-
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
methyl-1-(sulfanylmethyl)hexanoate
N-((5-bromo-2-methyl-1(phenylsulfonyl)-1H-indol-3-yl)methyl) hydroxylamine
AtPDF2
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
N-(2-methoxybenzoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(2-[[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(4-hydroxyphenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-2,4-dimethylphenyl)-1-[(2S)-2-[(1S)-2-(hydroxyamino)-1-(hydroxysulfanyl)-2-oxoethyl]hexanoyl]-L-prolinamide
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloheptadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclohexadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloicos-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclotridec-6-yl)-methyl-N-hydroxy-formamide
-
N-(4-((Z)-phenyldiazenyl) phenyl)-5-((Z)-styryl)-1,3,4-thiadiazol-2-amine
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(4-nitrophenyl)-N2-[2-(sulfanylmethyl)hexanoyl]lysinamide
-
N-(5-(3,4-dimethoxy phenyl)-1,3,4-thiadiazol-2-yl)-5-methylisoxazol-3-amine
-
-
N-(5-chloro-2,4-dimethoxyphenyl)-2-(4-ethyl-6-oxo-2-phenylpyrimidin-1(6H)-yl)acetamide
VIT1024538, docking into PfPDF-Co2+-actinonin complex
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(benzyloxy)-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-(cyclobutylcarbamoyl)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-L-prolinamide
active against Staphylococcus aureus, Haemophilus influenzae, and Streptomyces pneumoniae strains
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine amide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-alkyl urea hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000003 mM
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-benzoyl-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-benzyloxycarbonyl-Leu-norleucinal
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-formyl-L-methionylalanine
-
inhibition above 4 mM
N-formyl-Met-Ala-Ser
-
the enzyme activity of truncated PDF-1DeltaN37 is inhibited by an excess of N-formyl-Met-Ala-Ser substrate
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
N-formyl-N-hydroxy-3-phenylpropylamine
N-formylhydroxylamine
-
i.e. LBM-415
N-hydroxy urea
-
IC50 against Escherichia coli peptide deformylase: 0.0022 mM
N-hydroxy-2-(1H-indol-3-yl)acetamide
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
N-hydroxy-2-(3-oxo-3,4-dihydro-2H-1,3lambda4,2,4-benzodithiadiazin-2-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
N-hydroxy-2-(substituted phenyl) acetamide
-
-
N-hydroxy-2-[2-oxo-5-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl]acetamide
-
IC50: 0.00023 mM
N-hydroxy-5-([[2-(propan-2-yl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-5-([[4-(trifluoromethyl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
N-hydroxy-N-(3-hydrazino-3-oxopropyl)formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
N-hydroxy-N2-[(1-hydroxycyclopentyl)(phenyl)acetyl]valinamide
-
N-methoxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-methoxy-N-methyl-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-oxo-2-[3-oxo-4-(2-phenylethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-(tetrahydro-2H-pyran-2-ylmethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-substituted methionine hydrazide
-
IC50 against Escherichia coli peptide deformylase: 0.2 mM
N-sulfonyl-L-Val-L-Leu-hydroxamate
-
-
N-trans-caffeoyltyramine
IC50: 0.0108 mM
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(2-methoxyethyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N-hydroxy-N2-(3-methylbutyl)glycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(2-cyclopentylethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclobutylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopropylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]alanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]leucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]norleucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]phenylalanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl]hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
N-[(2R)-2-(cyclopentylmethyl)-3-[2-(furan-2-carbonyl)-1,2-diazinan-1-yl]-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide
-
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R,4S)-2-butyl-4-[[(2-fluorophenyl)carbamoyl]amino]-5-methyl-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(2R,4S)-2-butyl-5-methyl-4-[[(5-methylpyridin-2-yl)carbamoyl]amino]-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(2S)-2-[(2R)-2-(1,3-benzoxazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
active against Mycobacterium tuberculosis strains
N-[(2S)-2-[(2R)-2-(1H-benzimidazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
active against Mycobacterium tuberculosis strains
N-[(3,5-difluorophenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
binding structure, overview
N-[(3,5-difluorophenyl)carbamoyl]-3-methyl-L-valyl-N2-cyclopentyl-N-hydroxyglycinamide
cytotoxic IC50 values for compound PMT497 are 0.0209 mM against MDA-MB-231 and 0.0212 mM against MDA-MB-468 cell lines
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(4-formyl-3,5-diiodophenyl)methyl]-N-hydroxyformamide
-
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[2-(5-bromo-2-methyl-1H-indole-3-yl)methyl]hydroxylamine
AtPDF2
N-[2-(cyclopentylmethyl)-3-[(2S)-2-[(1,3-dicyclopropyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]-3-oxopropyl]-N-hydroxyformamide
N-[2-([(2S)-2-[(1,3-diphenyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl)hexyl]-N-hydroxyformamide
N-[3-(4-acetamidobutyl)-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl]methyl-N-hydroxy-formamide
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacycloicos-6-yl]methyl-N-hydroxyformamide
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacyclopentadec-6-yl]methyl-N-hydroxyformamide
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[4'-(2-cyclopropyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)[1,1'-biphenyl]-2-sulfonyl]benzamide
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(trifluoromethyl)benzoyl]-L-Met
-
time-dependent inhibition of zinc and cobalt deformylase, inhibition of full-length Co-PDF is competitive
N-[4-(trifluoromethyl)benzoyl]-L-Met hydrazide
-
time-dependent inhibition of zinc and cobalt deformylase
N-[[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]methyl]-N-hydroxyacetamide
-
N-[[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]methyl]-N-hydroxyformamide
-
Zn-BbPDF1-HT
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
N2-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-N-phenyl-L-lysinamide
-
N2-(benzenesulfinyl)-N2-butyl-N-hydroxyglycinamide
-
N2-(benzenesulfonyl)-N2-butyl-N-hydroxyglycinamide
-
N2-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-L-lysinamide
-
N2-[(2R)-2-[[hydroxy(oxo)-lambda5-phosphanyl]oxy]hexanoyl]-N-(4-nitrophenyl)-D-leucinamide
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxohexan-2-yl]-L-leucinamide
-
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
naphthalen-1-yl[[3-(trifluoromethyl)benzyl]amino]acetic acid
-
p-chloromercuribenzoate
-
potent inhibitor, IC50: 0.07 mM
Phe-Arg-beta-naphthylamide
-
-
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
polylethylene glycol
-
competitive inhibitor with respect to formylmethionine
-
protosappanin B
with high score in enzyme docking analysis
pseudopeptide metabolites
-
IC50 against Escherichia coli peptide deformylase: 0.000030 mM
-
pyrrolidine bicyclic(P2'/P3')compounds
-
-
-
quinazoline hydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00012 mM
reverse hydroxamate
British Biotech BB-83698
reverse hydroxamates
-
-
-
siRNA HsPDF 581-601
transfection of HeLa cells
-
siRNA HsPDF 659-679
transfection of HeLa cells
-
SKI-AC-1
IC50: 0.000072 mM, actionin analog
SKI-AC-10
IC50: 0.000078 mM, actionin analog
SKI-AC-11101
IC50: 0.000076 mM, actionin analog
-
SKI-AC-111101
IC50: 0.0000600 mM, actionin analog
SKI-AC-111110
IC50: 0.000427 mM, actionin analog
-
SKI-AC-111111
IC50: 0.000069 mM, actionin analog
SKI-AC-111112
IC50: 0.000234 mM, actionin analog
-
SKI-AC-111113
IC50: 0.000177 mM, actionin analog
-
SKI-AC-111114
IC50: 0.000300 mM, actionin analog
-
SKI-AC-11112
IC50: 0.000365 mM, actionin analog
-
SKI-AC-11113
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11114
IC50: 0.000276 mM, actionin analog
-
SKI-AC-11115
IC50: 0.000473 mM, actionin analog
-
SKI-AC-11116
IC50: 0.000335 mM, actionin analog
-
SKI-AC-11117
IC50: 0.000086 mM, actionin analog
SKI-AC-11118
IC50: 0.000115 mM, actionin analog
SKI-AC-11119
IC50: 0.000134 mM, actionin analog
-
SKI-AC-11128
IC50: 0.000522 mM, actionin analog
-
SKI-AC-11138
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11148
IC50: 0.0000600 mM, actionin analog
-
SKI-AC-11158
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11168
IC50: 0.000192 mM, actionin analog
-
SKI-AC-11178
IC50: 0.000200 mM, actionin analog
-
SKI-AC-11188
IC50: 0.000120 mM, actionin analog
SKI-AC-11198
IC50: 0.000090 mM, actionin analog
SKI-AC-3
IC50: 0.000500 mM, actionin analog
-
SKI-AC-5
IC50: 0.000400 mM, actionin analog
-
SKI-AC-51121
IC50: 0.000400 mM, actionin analog
-
SKI-AC-6
IC50: 0.000097 mM, actionin analog
SKI-AC-8
IC50: 0.000093 mM, actionin analog
SKI-AC-9
IC50: 0.000151 mM, actionin analog
-
SKI-AC-I-18
IC50: 0.000404 mM, actionin analog
-
SKI-AC-I-19
IC50: 0.000239 mM, actionin analog
-
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
theaflavin monogallate
-
-
thio peptide
-
IC50 against Escherichia coli peptide deformylase: 0.000019 mM, thiol chelating group combined with the best substrate motif
-
thioacetic acid S-[3-(5-bromo-1H-indol-3-yl)-2-oxopropyl] ester
AtPDF2
thioacetic acid S-[3-(indol-3-yl)-2-oxopropyl] ester
AtPDF2
thiol peptide
-
IC50 against Escherichia coli peptide deformylase: 0.0025 mM, designed based on the best substrate identified
-
Thiophenol
-
IC50: 0.5 mM
thyropropic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.001 mM
-
urea analogs(P2'/P3')of N-formyl hydroxylamine
-
-
[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]acetic acid
-
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
-
Zn-BbPDF1-HT
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
-
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
-
i.e. BB-3497
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
-
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
i.e. BB-83698
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
-
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
-
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
-
-
(2R)-N-[(3S)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4,4-dimethylpent-1-en-3-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
-
-
(2R)-N-[(3S)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4,4-dimethylpent-1-en-3-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-4H-pyrazol-3-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
active against Staphylococcus aureus and Escherichia coli strains
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-4H-pyrazol-3-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
active against Staphylococcus aureus and Escherichia coli strains
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(2Z)-2-(3-butyl-1,3-benzothiazol-2(3H)-ylidene)-N-hydroxyacetamide
-
(2Z)-2-(3-butyl-1,3-benzothiazol-2(3H)-ylidene)-N-hydroxyacetamide
active against Staphylococcus aureus strains
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
-
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
-
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
two-step tight-binding process, binding structure analysis
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
-
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
-
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
two-step tight-binding process
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
two-step tight-binding process, binding structure analysis
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
-
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
-
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
-
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
-
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
-
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(1H-pyrazol-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(1H-pyrazol-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-[(pyrimidin-2-yl)amino]phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-[(pyrimidin-2-yl)amino]phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(pyridin-3-yl)pyrimidin-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(pyridin-3-yl)pyrimidin-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(1H-benzimidazol-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(1H-benzimidazol-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(3-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(3-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(4-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(4-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(5-tert-butyl-1,2-oxazol-3-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(6S)-N-(5-tert-butyl-1,2-oxazol-3-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
-
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
-
-
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
1,10-phenanthroline
-
competitive with respect to N-formyl-Met-Val; time-dependent inhibition of cobalt-substituted enzyme with loss of the active site metal
1,10-phenanthroline
-
similar inhibition of Fe2+- and Co2+-bound enzyme
1,10-phenanthroline
-
competitive
1,10-phenanthroline
-
complete inhibition at 5 mM
1,10-phenanthroline
-
competitive with respect to N-formyl-Met-Val
1-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
-
-
1-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
-
-
1-(3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
-
-
1-(3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
-
-
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
-
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
-
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
-
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
-
1-[(2R)-2-[(2S)-1-(hydroxyamino)-1-oxopropan-2-yl]hexanoyl]-N-propyl-L-prolinamide
-
1-[(2R)-2-[(2S)-1-(hydroxyamino)-1-oxopropan-2-yl]hexanoyl]-N-propyl-L-prolinamide
active against Staphylococcus aureus strains
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
-
-
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
-
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
-
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
-
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
-
-
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
broadly active versus Escherichia coli and Bacillus subtilis strains
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
broadly active versus Escherichia coli and Bacillus subtilis strains
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
binding structure analysis
2-(2,2-dioxo-1,4-dihydro-2lambda6,1,3-benzothiadiazin-3(2H)-yl)-N-hydroxyacetamide
-
2-(2,2-dioxo-1,4-dihydro-2lambda6,1,3-benzothiadiazin-3(2H)-yl)-N-hydroxyacetamide
-
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
-
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
-
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
binding structure analysis
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.0031 mg/ml
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
broadly active versus Escherichia coli and Bacillus subtilis strains
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.006 mg/ml
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
broadly active versus Escherichia coli and Bacillus subtilis strains
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
-
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
binding structure analysis
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-bromo-2-methyl-1H-indolyl)-N-hydroxyacetamide
AtPDF2
2-(5-bromo-2-methyl-1H-indolyl)-N-hydroxyacetamide
-
-
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.013 mg/ml
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.025 mg/ml
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
-
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.027 mg/ml
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.04 mg/ml
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
-
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
-
2-(indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.16 mg/ml
2-(indol-3-yl)-N-hydroxyacetamide
-
MIC is 0.115 mg/ml
2-phenylethanamine
-
-
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
-
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
-
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
-
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
potently active versus Bacillus subtilis strains
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
-
-
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
-
2-[[formyl(hydroxy)amino]methyl]-N-[(5-methoxy-1H-benzimidazol-2-yl)methyl]hexanamide
potently active versus Escherichia coli strains and the Ni-PDF enzyme
2-[[formyl(hydroxy)amino]methyl]-N-[(5-methoxy-1H-benzimidazol-2-yl)methyl]hexanamide
potently active versus Staphylococcus aureus strains and the Ni-PDF enzyme
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
-
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
-
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
binding structure analysis
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
two-step tight-binding process
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
AtPDF2
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
-
MIC is 0.016 mg/ml
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
-
MIC is 0.12 mg/ml
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
-
-
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
-
-
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
-
-
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
-
-
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
poor antibacterial activity
6-chloro-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole
-
6-chloro-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole
-
-
actinonin
-
peptide deformylase 1 and 2
actinonin
slow, tight-binding inhibitor
actinonin
-
over 80% inhibition of the recombinant enzymatic activity is observed at 10 nM actinonin
actinonin
-
50% inhibition of enzyme Def at 95 nM, 50% inhibition of enzyme form YkrB by 130 nM
actinonin
-
MIC is 0.0013 mg/ml
actinonin
-
pseudo-peptide hydroxamate, potent inhibitor Kd: 0.3 nM
actinonin
-
MIC is 0.034 mg/ml
actinonin
i.e. 3-[(1-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-2-methylpropyl)carbamoyl]octanohydroxamic acid, a naturally occurring potent PDF inhibitor
actinonin
competitive inhibitor, binding in a two-step mechanism, determination and comparison of the three-dimensional structure of Escherichia coli PDF bound to actinonin
actinonin
-
IC50 against Escherichia coli peptide deformylase: 0.0000003 mM
actinonin
-
95% inhibition at 0.01 mM, competitive, locates near the active site and plugs the substrate tunnel to prevent the substrate from accessing the catalytic site
actinonin
-
competitive, IC50: 43 nM
actinonin
IC50: 0.000043 mM
actinonin
-
efficient inhibitor
actinonin
binding structure to the enzyme, overview
actinonin
enzyme inhibitor, inhibits the growth of both cancer and non-cancer cell lines
actinonin
-
complete inhibition at 0.005 mM
actinonin
modeling of effects of metal ions (Co2+, Zn2+, Ni2+ and Fe2+) on enzyme binding, overview. The PfPDF-Co2+-actinonin inhibitor complex is the energetically favorable structure, structure comparisons
actinonin
a naturally occurring PDF inhibitor
actinonin
-
actinonin does exert a significant inhibitory effect on enzyme activity in the presence of 0.25 mM substrate (complete inhibition at 10 nM)
actinonin
competitive inhibitor, binding in a two-step mechanism, determination and comparison of the three-dimensional structure of Vp16 PDF bound to actinonin
actinonin
analysis of the binding structure to XoPDF
BB-3497
-
-
BB-81384
-
-
BB-83698
-
BB-83698
Staphylococcus enteridis
-
-
BB-83698
Staphylococcus non-hemolyticus
-
-
BB83698
-
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
-
calpeptin
-
Ciprofloxacin
-
-
Diethylenetriaminepentaacetic acid
binding structure analysis, overview
Diethylenetriaminepentaacetic acid
binding structure analysis, overview
EDTA
-
convertion to the apoenzyme during 1 h at 10 mM
EDTA
-
slight inhibition at 10 mM
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
-
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
-
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
-
fumimycin
-
fumimycin
isolated from the fermentation broth of Aspergillus fumisynnematus strain F746
GSK-1322322
-
GSK1322322
-
GSK1322322
-
a antibacterial agent under development, it shows antibacterial activities against multidrug-resistant respiratory and skin pathogens through its inhibition of the bacterial peptide deformylase. Analysis of the effects of GSK1322322 on the human gut microbiome, microbiome data analysis, overview
GSK1322322
-
an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview
GSK1322322
-
an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview
GSK1322322
-
an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview
GSK1322322
Streptomyces pneumoniae
-
an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview
H2O2
slight inhibition, binding structure analysis, overview
H2O2
binding structure analysis, overview
hematoxylin
-
-
imino[(5-methoxy-5-oxo-4-[2-(sulfanylmethyl)hexanoyl]aminopentyl)amino]methaneamine
-
-
imino[(5-methoxy-5-oxo-4-[2-(sulfanylmethyl)hexanoyl]aminopentyl)amino]methaneamine
-
-
isoxazole-3-hydroxamic acids
23 different compounds were synthesized and compared to the inhibitory activity of actinonin
-
isoxazole-3-hydroxamic acids
-
23 different compounds were synthesized and compared to the inhibitory activity of actinonin
-
LBM-415
-
LBM-415
Staphylococcus enteridis
-
-
LBM-415
Staphylococcus non-hemolyticus
-
-
LBM415
-
-
linezolid
-
-
macrolactin N
-
macrolactin N
isolated from Bacillus subtilis culture medium, has antibacterial activity on Staphylococcus aureus and Escherichia coli strains
macrolactin N
isolated from Bacillus subtilis culture medium, has antibacterial activity on Staphylococcus aureus and Escherichia coli strains
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
-
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
-
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
-
methyl-1-(sulfanylmethyl)hexanoate
-
-
methyl-1-(sulfanylmethyl)hexanoate
-
-
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
-
-
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
-
-
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
-
-
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
AtPDF2
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
-
MIC is 0.035 mg/ml
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
-
MIC is 0.065 mg/ml
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(4-hydroxyphenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(4-hydroxyphenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(2-[[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
-
-
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
-
-
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
-
-
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
-
-
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
-
-
N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-benzyloxycarbonyl-Leu-norleucinal
-
most potent competitive inhibitor
N-benzyloxycarbonyl-Leu-norleucinal
-
most potent competitive inhibitor
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
-
i.e. SB 543668, IC50: 0.00115 mM
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
-
i.e. SB 543668, IC50: 0.00032 mM
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
-
i.e. SB 543668, IC50: 0.0022 mM
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
-
i.e. SB 543668, IC50: 0.0039 mM
N-formyl-N-hydroxy-3-phenylpropylamine
-
i.e. SB 485345, IC50: 0.00016 mM
N-formyl-N-hydroxy-3-phenylpropylamine
-
i.e. SB 485345, IC50: 0.00015 mM
N-formyl-N-hydroxy-3-phenylpropylamine
-
i.e. SB 485345, IC50: 0.00025 mM
N-formyl-N-hydroxy-3-phenylpropylamine
-
i.e. SB 485345, IC50: 0.0004 mM
N-hydroxy-2-(1H-indol-3-yl)acetamide
-
N-hydroxy-2-(1H-indol-3-yl)acetamide
-
N-hydroxy-2-(1H-indol-3-yl)acetamide
-
N-hydroxy-2-(1H-indol-3-yl)acetamide
-
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
-
IC50: 0.0029 mM
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
-
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
-
N-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
-
-
N-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
-
-
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
-
-
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
-
-
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
-
-
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
-
i.e. SB 505684, IC50: 0.0028 mM
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
-
i.e. SB 505684, IC50: 0.00104 mM
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
-
i.e. SB 505684, IC50: 0.00109 mM
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
-
i.e. SB 505684, IC50: 0.0022 mM
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
binding structure, overview
N-[(2R)-2-(cyclopentylmethyl)-3-(2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl]hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl]hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
i.e. GSK1322322
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
-
-
N-[2-(cyclopentylmethyl)-3-[(2S)-2-[(1,3-dicyclopropyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]-3-oxopropyl]-N-hydroxyformamide
-
-
N-[2-(cyclopentylmethyl)-3-[(2S)-2-[(1,3-dicyclopropyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]-3-oxopropyl]-N-hydroxyformamide
-
-
N-[2-([(2S)-2-[(1,3-diphenyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl)hexyl]-N-hydroxyformamide
-
-
N-[2-([(2S)-2-[(1,3-diphenyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl)hexyl]-N-hydroxyformamide
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
active against Staphylococcus aureus and Streptomyces pneumoniae strains
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[3-[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[3-[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
-
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
-
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
-
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
-
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
-
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
-
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
-
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
-
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
-
Ni2+
addition of 1 mM Ni2+ increases the PDF activity by 70%, with 20 mM Ni2+, the activity decreases by 23% compared with the low Ni2+ concentration
Ni2+
-
less than 40% residual activity at 0.1 mM
penicillin
-
-
Peptide aldehydes
-
peptide aldehydes containing a methional or leucinal
Peptide aldehydes
-
peptide aldehydes containing a methional or leucinal
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
-
-
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
-
-
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
-
-
propan-2-amine
-
-
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
-
i.e. VRC-3375
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
-
-
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
-
-
theaflavin
-
-
Vancomycin
-
-
VIC-104959
-
LBM415
VRC-3375
-
-
VRC-4307
-
-
Zn2+
-
converting enzyme to inactive state
Zn2+
-
tightly bound, very poor activity
additional information
inhibitor design with the enzyme as model, structure-activity relationship analysis, overview. Design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug-resistant clinical isolate. Determination of minimal inhibitory concentrations of oxadiazole compounds for antibacterial activity on Escherichia coli strains. Three-dimensional comparison of the binding between various PDF inhibitors and actinonin
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
-
the results of the study may provide the basis for the design of more potent and selective deformylase inhibitors as potential antibacterial agents
-
additional information
theoretical study of Escherichia coli peptide deformylase inhibition by several drugs
-
additional information
-
theoretical study of Escherichia coli peptide deformylase inhibition by several drugs
-
additional information
-
synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria, MIC values, structure-activity relationships, overview
-
additional information
biphenyl tetrazole-thiazolidinediones as bacterial peptide deformylase inhibitors: synthesis, biological evaluations, and molecular docking study, overview. MIC values with Escherichia coli and Bacillus subtilis cells
-
additional information
-
biphenyl tetrazole-thiazolidinediones as bacterial peptide deformylase inhibitors: synthesis, biological evaluations, and molecular docking study, overview. MIC values with Escherichia coli and Bacillus subtilis cells
-
additional information
cacterial peptide deformylase inhibition of cyano-substituted biaryl analogues, synthesis, in vitro biological evaluation, molecular docking study, and in silico ADME (absorption, distribution, metabolism, excretion) prediction, overview. Structure-activity studies. In vitro antibacterial activity analysis of the synthesized compounds against Escherichia coli strain NCIM-2256 and Bacillus subtilis strain NCIM-2063
-
additional information
-
cacterial peptide deformylase inhibition of cyano-substituted biaryl analogues, synthesis, in vitro biological evaluation, molecular docking study, and in silico ADME (absorption, distribution, metabolism, excretion) prediction, overview. Structure-activity studies. In vitro antibacterial activity analysis of the synthesized compounds against Escherichia coli strain NCIM-2256 and Bacillus subtilis strain NCIM-2063
-
additional information
molecular docking and screening of designed small molecule ligands, a critical arginine residue in peptide deformylase for spiro cyclopropyl PDF inhibitor's extra hydrophobic binding is identified. Compund synthesis and structure confirmation by LC-MS, 1H NMR, 13C NMR, and HRMS. The compounds are evaluated through in vitro antibacterial activity assay, some are further subjected to in vivo rat pharmacokinetic assessment. Spiro cyclopropyl proline N-formyl hydroxylamines, and especially the bioisosteric azoles, are a promising class of PDF inhibitors
-
additional information
design and synthesis of 4-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methyl)biphenyl-2-carbonitrile analogues as bacterial peptide deformylase inhibitors, structure-activity relationship analysis, docking study, detailed overview. Antibacterial activity compared to standard ampicillin, MIC values for Escherichia coli and Bacillus subtilis
-
additional information
-
design and synthesis of 4-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methyl)biphenyl-2-carbonitrile analogues as bacterial peptide deformylase inhibitors, structure-activity relationship analysis, docking study, detailed overview. Antibacterial activity compared to standard ampicillin, MIC values for Escherichia coli and Bacillus subtilis
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview. Poor inhibition by 23 and 24
-
additional information
ligand and structure-based approaches for identification of peptide deformylase inhibitors as antibacterial drugs, development of pharmacophore models, molecular docking using the crystal structure of Escherichia coli PDF (PDB ID 1G2A), in silico pharmacokinetic and toxicity prediction studies, overview. Computer-aided drug design (CADD)
-
additional information
-
ligand and structure-based approaches for identification of peptide deformylase inhibitors as antibacterial drugs, development of pharmacophore models, molecular docking using the crystal structure of Escherichia coli PDF (PDB ID 1G2A), in silico pharmacokinetic and toxicity prediction studies, overview. Computer-aided drug design (CADD)
-
additional information
-
molecular docking studies of 1,3,4-thiadiazoles as peptide deformylase inhibitors, molecular modeling of the enzyme binding mode, docking study using the structure of Escherichia coli enzyme (PDB ID 1G27) complexed with inhibitor Bb-3497, overview. The compounds are potential antibacterial agents. Enzyme binding involves residues Gly45, Gly89, Glu95, Cys90, Leu91, Leu46, Met 38, Ile44, and Ile128
-
additional information
inhibitor design with the enzyme as model, structure-activity relationship analysis, overview. Design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug-resistant clinical isolate. Determination of minimal inhibitory concentrations of oxadiazole compounds for antibacterial activity on Escherichia coli strains. Three-dimensional comparison of the binding between various PDF inhibitors and actinonin
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
-
inhibition mechanism and kinetics, overview. No significant inhibition by caffeic acid, ferulic acid, chlorogenic acid, genistein, curcumin, naringenin, hesperitin, chrysin,apigenin, luteolin, kaempferol, myricetin, silibinin, and rutin at 0.01 mM
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
-
development of a high-throughput assay to screen for inhibitors
-
additional information
-
purified thioredoxin-fused PDF containing Fe2+ ion is inactivated during purification
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
-
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
structure-based drug design of small molecule peptide deformylase inhibitors to treat cancer, molecular docking studies revealing that M7594_0037 and its three derivatives interact with HsPDF by several conserved hydrogen bonds. Compound synthesis using the crystal structure of the HsPDF complex with actinonin (PDB ID 3G5K) as template
-
additional information
-
structure-based drug design of small molecule peptide deformylase inhibitors to treat cancer, molecular docking studies revealing that M7594_0037 and its three derivatives interact with HsPDF by several conserved hydrogen bonds. Compound synthesis using the crystal structure of the HsPDF complex with actinonin (PDB ID 3G5K) as template
-
additional information
iron-containing PDFs are sensitive to treatment with oxidizing agents because of oxidation of Fe2+ to Fe3+ at the metal binding core
-
additional information
-
iron-containing PDFs are sensitive to treatment with oxidizing agents because of oxidation of Fe2+ to Fe3+ at the metal binding core
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
structure-based pharmacophore screening with PfPDF-Co2+-actinonin complex, modeling, and ADME (adsorption, distribution, metabolism, and excretion) properties determination. Model validation. Inhibitor docking study, overview
-
additional information
iron-containing PDFs are sensitive to treatment with oxidizing agents because of oxidation of Fe2+ to Fe3+ at the metal binding core
-
additional information
-
iron-containing PDFs are sensitive to treatment with oxidizing agents because of oxidation of Fe2+ to Fe3+ at the metal binding core
-
additional information
-
there is no significant inhibitory effect of actinonin on enzyme activity when the concentration of substrate is 4 mM
-
additional information
-
effects of inhibitors on the enzyme structure, overview
-
additional information
-
synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria, MIC values, structure-activity relationships, overview
-
additional information
molecular docking and screening of designed small molecule ligands, a critical arginine residue in peptide deformylase for spiro cyclopropyl PDF inhibitor's extra hydrophobic binding is identified. Compund synthesis and structure confirmation by LC-MS, 1H NMR, 13C NMR, and HRMS. The compounds are evaluated through in vitro antibacterial activity assay, some are further subjected to in vivo rat pharmacokinetic assessment. Spiro cyclopropyl proline N-formyl hydroxylamines, and especially the bioisosteric azoles, are a promising class of PDF inhibitors
-
additional information
PDF-based virtual screening of compounds from Traditional Chinese Medicine (TCM) and discovery of antibacterial natural compounds via inhibition of peptide deformylase, MIC values, overview
-
additional information
-
PDF-based virtual screening of compounds from Traditional Chinese Medicine (TCM) and discovery of antibacterial natural compounds via inhibition of peptide deformylase, MIC values, overview
-
additional information
different classes of PDF inhibitors, structures, and molecular modeling studies, overview
-
additional information
-
synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria, MIC values, structure-activity relationships, overview
-
additional information
inhibitor design with the enzyme as model, structure-activity relationship analysis, overview. Design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug-resistant clinical isolate. Determination of minimal inhibitory concentrations of oxadiazole compounds for antibacterial activity on Escherichia coli strains. Three-dimensional comparison of the binding between various PDF inhibitors and actinonin
-
additional information
-
inhibitor design with the enzyme as model, structure-activity relationship analysis, overview. Design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug-resistant clinical isolate. Determination of minimal inhibitory concentrations of oxadiazole compounds for antibacterial activity on Escherichia coli strains. Three-dimensional comparison of the binding between various PDF inhibitors and actinonin
-
additional information
-
not inhibited by actinonin
-
additional information
actinonin binding structure comparisons of enzymes from different sources
-
additional information
-
actinonin binding structure comparisons of enzymes from different sources
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000007
(2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.000002
(2R)-N4-hydroxy-N1-[(2R)-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.00104
(2Z)-2-(3-butyl-1,3-benzothiazol-2(3H)-ylidene)-N-hydroxyacetamide
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.000023 - 0.00003
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
0.000006 - 0.000077
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
0.000017 - 0.0003
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
0.000007 - 0.000119
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
0.00001
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
0.0000035 - 0.000058
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
0.000016 - 0.00055
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
0.000049
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
Mycobacterium tuberculosis
-
0.000803
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
Mycobacterium tuberculosis
-
0.000018
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
Mycobacterium tuberculosis
-
0.000202
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
Mycobacterium tuberculosis
-
0.000155
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000011 - 0.0005
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
0.000014 - 0.000909
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
0.00019
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00016
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000027 - 0.00046
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
0.000128 - 0.006
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
0.0259
(E)-1,5-dimethyl-2-phenyl-4-((5-styryl-1,3,4-thiadiazol-2-yl)amino-1,2-dihydro-3H-pyrazole-3-one)
Escherichia coli
-
pH and temperature not specified in the publication
0.0355
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,4-dimethoxybenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0265
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,5-dimethoxybenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.01725
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,6-dichlorobenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.018
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2-chlorobenzylidene)thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.033
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4,5-trimethoxybenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.02675
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4-dimethoxybenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.01625
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-chlorobenzylidene)thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.02625
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-fluorobenzylidene)thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.026
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-methoxybenzylidene) thiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0205
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-benzylidenethiazolidine-2,4-dione
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0284
(E)-5-methyl-N-(5-styryl-1,3,4-thiadiazole-2-yl)isoxazol-3-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0224
(E)-5-styryl-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0652
(E)-N-(furan-2-ylmethyl)-5-styryl-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.00125
(E)-N-phenethyl-3-(3,4-diacetoxyphenyl)acrylamide
Helicobacter pylori
IC50: 0.00125 mM
0.0001
(RS)- and (SR)-3-[(RS)-benzenesulfinyl]heptanoic acid hydroxyamide
Escherichia coli
-
mixture of both components, IC50: 0.0001 mM, possible antimicrobial agent
0.000035
(RS)-3-(phenylsulfonyl)heptanoic acid hydroxyamide
Escherichia coli
-
IC50: 0.035 micro molar, possible antimicrobial agent
0.323
(Z)-4-hydroxy-3-(5-((4-(phenyldiazenyl) phenyl) amino)-1,3,4-thiadiazol-2-yl)benzene sulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.2061
(Z)-5-(3,4-dimethoxyphenyl)-N-(4-(phenyl diazenyl) phenyl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0277
(Z)-N-(4-methylpyridine-2-yl)-5-styryl-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.000116
1-[(2-methoxyphenyl)carbamoyl]prolyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.00002
1-[(2R)-2-[(2S)-1-(hydroxyamino)-1-oxopropan-2-yl]hexanoyl]-N-propyl-L-prolinamide
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.0000013 - 0.000018
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
0.0000015 - 0.00001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
0.0000008 - 0.000007
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
0.0000012 - 0.0000055
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
0.00000054 - 0.0000077
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
0.00000044 - 0.0000049
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
0.000001 - 0.000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
0.0000019 - 0.000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
0.00000046 - 0.0000061
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
0.0000021 - 0.00002
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
0.0000011 - 0.0000088
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
0.00000077 - 0.0000069
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
0.00000019 - 0.0000041
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
0.00000026 - 0.0000031
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
0.00000048 - 0.0000047
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
0.00000066 - 0.0000044
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
0.00000015 - 0.0000043
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
0.00000041 - 0.0000061
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
0.00000035 - 0.0000059
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
0.00000037 - 0.0000047
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
0.00000035 - 0.0000044
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
0.0041
2',2'-bisepigallocatechin monogallate
Homo sapiens
-
fluorescence polarization assay
0.000008 - 0.0004
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
0.002
2-(1-benzyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.002 mM
0.00059
2-(1-butyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00059 mM
0.00076
2-(2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00076 mM
0.00012
2-(2,2-dioxo-1,4-dihydro-2lambda6,1,3-benzothiadiazin-3(2H)-yl)-N-hydroxyacetamide
Escherichia coli
pH and temperature not specified in the publication
0.00036 - 0.000703
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
0.000012
2-(4-benzyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000058
2-(4-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000069
2-(5-bromo-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.000069 mM
0.000037 - 0.00036
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
0.000098
2-(5-bromo-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.000098 mM
0.000049
2-(5-bromo-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.000049 mM
0.00011
2-(5-chloro-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00011 mM
0.00012
2-(5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00012 mM
0.00031
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
Escherichia coli
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00031 mM
0.027
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide
Escherichia coli
-
IC50: 0.027 mM
0.00087
2-(5-fluoro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00087 mM
0.00087
2-(5-fluoro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00087 mM
0.05
2-(biphenyl-4-yl)-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0076
2-butyl-5,7-dimethyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
Escherichia coli
-
belongs to a class of angiotensin II receptor antagonists, potent inhibitor, IC50: 0.0076 mM
0.00000012 - 0.0000036
2-phenylethanamine
0.00402
2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Helicobacter pylori
pH and temperature not specified in the publication
0.00166
2-thioxo-4-thiazolidinone N-hexanoic acid
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.00166 mM
0.00074
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00013
2-[2,2-dioxido-5-(trifluoromethyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00013 mM
0.00005
2-[4-(3,3-dimethyl-2-oxobutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000005
2-[4-(3-methylbutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000041
2-[4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.00029
2-[5-chloro-2,2-dioxido-1-(3-phenylpropyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
Escherichia coli
-
IC50: 0.00029 mM
0.00011 - 0.000251
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
0.0995
3-(5-((4H-1,2,4-triazol-4-yl)amino)-1,3,4-thiadiazol-2-yl)-4-hydroxy benzenesulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.4819
3-(5-((furan-2-ylmethyl)amino)-1,3,4-thiadiazole-2-yl)-4-hydroxybenzenesulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.2753
3-(5-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]-4H-1,2,4-triazol-3-yl)-4-hydroxybenzenesulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.0025
3-methoxy-7-methyl-1,3-dihydro-2-benzofuran-4,5,6-triol
Staphylococcus aureus
pH and temperature not specified in the publication
0.031
3-methoxycatechol
Homo sapiens
-
fluorescence polarization assay
0.000043
3-methyl-N-(1,3-thiazol-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000052
3-methyl-N-(2-methylpropanoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000028
3-methyl-N-(morpholin-4-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000017
3-methyl-N-(phenylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000047
3-methyl-N-(piperidin-1-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000054
3-methyl-N-(pyridin-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000049
3-methyl-N-(pyridin-3-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000065
3-methyl-N-(pyridin-4-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000019
3-methyl-N-(thiophen-2-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.00005
3-methyl-N-[methyl(phenyl)carbamoyl]-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.0342
3-[5'-benzyl-2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
Escherichia coli
-
potent inhibitor, IC50: 0.0342 mM, the acidic moiety forms direct ionic interactions with active site metal cation
0.033
4'-((2-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.01566
4'-((2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.02091
4'-((3-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0425
4'-((3-fluoro-4-morpholinophenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.025
4'-((3-nitrophenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0335
4'-((4-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.05116
4'-((4-carboxyphenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.02825
4'-((4-chloro-2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.03458
4'-((4-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.05075
4'-((4H-1,2,4-triazol-4-ylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.02775
4'-((6-methoxybenzothiazol-2-ylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.01316
4'-((phenylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.01916
4'-((pyrazin-2-ylamino)methyl)biphenyl-2-carbonitrile
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0039
4'-(2-ethyl-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl)[1,1'-biphenyl]-2-carboxylic acid
Escherichia coli
pH and temperature not specified in the publication
0.3043
4-((5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazol-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
Escherichia coli
-
pH and temperature not specified in the publication
0.000075 - 0.0082
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
0.00002 - 0.00065
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
0.1035
4-hydroxy-3-(5-((5-methylisoxazol-3-yl)amino)-1,3,4-thiadiazol-2-yl)benzenesulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.1279
4-hydroxy-3-(5-[(4-methylpyridin-2-yl)amino]-4H-1,2,4-triazol-3-yl)benzenesulfonic acid
Escherichia coli
-
pH and temperature not specified in the publication
0.0036
4-methyl-1,3-dihydro-2-benzofuran-1,5,6,7-tetrol
Staphylococcus aureus
pH and temperature not specified in the publication
0.0037
5,5'-disulfanediyldi(1,3,4-thiadiazol-2-amine)
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.1725
5-(3,4-dimethoxyphenyl)-N-(4-methylpyridine-2-yl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0972
5-(3,4-dimethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.2743
5-(3,4-dimethoxyphenyl)-N-(furan-2-ylmethyl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0034
5-([[(1-benzothiophen-2-yl)methyl]sulfanyl]methyl)-N-hydroxy-1,2-oxazole-3-carboxamide
Escherichia coli
pH and temperature not specified in the publication
0.129
5-amino-1,3,4-thiadiazole-2-thiol
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.0162
5-bromo-7-methyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.0039
5-chloro-2-propyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
Escherichia coli
-
belongs to a broad class of angiotensin II receptor antagonists, potent competitive inhibitor, IC50: 0.0039 mM, the acidic moiety forms direct ionic interactions with active site metal cation
0.01
5-chloro-2-propyl-3-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-3H-imidazo[4,5-b]pyridine
Escherichia coli
pH and temperature not specified in the publication
0.0038
5-[[(2-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.002
5-[[(3,4-dichlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0017
5-[[(3-chlorophenyl)sulfonyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0008 - 0.0023
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
0.0065
5-[[(4-methoxyphenyl)sulfonyl]methyl]-1,2-oxazole-3-carbohydrazide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0039
6-chloro-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole
Escherichia coli
pH 7.4, 30°C, recombinant enzyme
0.017
7,8-dihydroxyflavone
Homo sapiens
-
fluorescence polarization assay
0.0000003 - 0.0055
actinonin
0.01
aldehyde peptide
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.01 mM
-
0.000004 - 0.00001
alkyl-succinate-proline hydroxamate
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.000004-0.000010 mM
0.000005
benzothiazinone derivatives
Haemophilus influenzae
-
IC50: 0.000005 mM
-
0.00104
benzothiazolylidene hydroxamic acid derivatives
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.00104 mM
-
0.000016
beta-sulfonylhydroxamic acid
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.000016 mM
0.015
butyl {[4'-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)-5-(2-methylbutan-2-yl)biphenyl-2-yl]sulfonyl}carbamate
Escherichia coli
-
competitive inhibition, IC50: 0.015 mM, the acidic moiety forms direct ionic interactions with active site metal cation
0.00402
caffeic acid phenethyl ester
Helicobacter pylori
-
pH and temperature not specified in the publication
0.048
chloranil
Homo sapiens
-
fluorescence polarization assay
0.038
epigallocatechin 3,5-digallate
Homo sapiens
-
fluorescence polarization assay
0.029
epitheaflavin monogallate
Homo sapiens
-
fluorescence polarization assay
0.00011
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.0358
flavimycin A
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.1001
flavimycin B
Staphylococcus aureus
-
pH and temperature not specified in the publication
0.0041
fumimycin
Staphylococcus aureus
pH and temperature not specified in the publication
0.000043
GLLI
Homo sapiens
IC50: 0.000043 mM
0.012
hematein
Homo sapiens
-
fluorescence polarization assay
0.0027
hematoxylin
Homo sapiens
-
fluorescence polarization assay
0.0002
hydantoin
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.0002 mM
0.017
irigenol
Homo sapiens
-
fluorescence polarization assay
0.0034
isoxazole-3-hydroxamic acid derivatives
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.0034 mM
-
0.0075
macrolactin N
Staphylococcus aureus
pH and temperature not specified in the publication
0.00033
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000011
N-(2-methoxybenzoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.0165
N-(4-((Z)-phenyldiazenyl) phenyl)-5-((Z)-styryl)-1,3,4-thiadiazol-2-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.0915
N-(5-(3,4-dimethoxy phenyl)-1,3,4-thiadiazol-2-yl)-5-methylisoxazol-3-amine
Escherichia coli
-
pH and temperature not specified in the publication
0.00000019 - 0.0000065
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00023
N-(benzyloxy)-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0000003 - 0.0000018
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.0000007 - 0.000009
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.0000002 - 0.000004
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.000055
N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.0000005 - 0.0000052
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.0000001 - 0.000002
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00000043 - 0.0000061
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00000052 - 0.0000034
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00000022 - 0.0000024
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.000004 - 0.000016
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.000003
N-alkyl urea hydroxamate
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.000003 mM
0.00000028 - 0.0000052
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.000041
N-benzoyl-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.00000091 - 0.0000048
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00032 - 0.0022
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
0.00015 - 0.00025
N-formyl-N-hydroxy-3-phenylpropylamine
0.0022
N-hydroxy urea
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.0022 mM
0.000005 - 0.0029
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
0.000005
N-hydroxy-2-(3-oxo-3,4-dihydro-2H-1,3lambda4,2,4-benzodithiadiazin-2-yl)acetamide
Escherichia coli
pH and temperature not specified in the publication
0.00023
N-hydroxy-2-[2-oxo-5-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl]acetamide
Escherichia coli
-
IC50: 0.00023 mM
0.0076
N-hydroxy-5-([[2-(propan-2-yl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0087
N-hydroxy-5-([[4-(trifluoromethyl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.00104 - 0.0028
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
0.000074
N-methoxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.002
N-methoxy-N-methyl-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000005
N-oxo-2-[3-oxo-4-(2-phenylethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.000018
N-oxo-2-[3-oxo-4-(tetrahydro-2H-pyran-2-ylmethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0004
N-oxo-2-[3-oxo-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.2
N-substituted methionine hydrazide
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.2 mM
0.0108
N-trans-caffeoyltyramine
Helicobacter pylori
IC50: 0.0108 mM
0.00000038 - 0.000007
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.000042
N-[(2-methoxyethyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000021
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N-hydroxy-N2-(3-methylbutyl)glycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000031
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(2-cyclopentylethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000013
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclobutylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000029
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000015
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopropylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000042
N-[(2-methoxyphenyl)carbamoyl]alanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000032
N-[(2-methoxyphenyl)carbamoyl]leucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000036
N-[(2-methoxyphenyl)carbamoyl]norleucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000061
N-[(2-methoxyphenyl)carbamoyl]phenylalanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000013
N-[(2-methoxyphenyl)carbamoyl]valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.000005
N-[(2R)-2-(cyclopentylmethyl)-3-[2-(furan-2-carbonyl)-1,2-diazinan-1-yl]-3-oxopropyl]-N-hydroxyformamide
Escherichia coli
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.000013
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000013
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000028
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000015
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.00001
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000024
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000021
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000161
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000008
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000068
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
Mycobacterium tuberculosis
-
0.000013
N-[(2S)-2-[(2R)-2-(1,3-benzoxazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
Mycobacterium tuberculosis
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.00001
N-[(2S)-2-[(2R)-2-(1H-benzimidazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
Mycobacterium tuberculosis
pH and temperature not specified in the publication, versus Ni-PDF enzyme
0.00000072 - 0.0000063
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.00000051 - 0.0000058
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.0000003 - 0.0000023
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
0.0228
N-[4'-(2-cyclopropyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)[1,1'-biphenyl]-2-sulfonyl]benzamide
Escherichia coli
pH and temperature not specified in the publication
0.00013
N2-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-N-phenyl-L-lysinamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.076
N2-[(2R)-2-[[hydroxy(oxo)-lambda5-phosphanyl]oxy]hexanoyl]-N-(4-nitrophenyl)-D-leucinamide
Escherichia coli
pH and temperature not specified in the publication, versus Fe-PDF enzyme
0.015
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxohexan-2-yl]-L-leucinamide
Bacillus subtilis
pH and temperature not specified in the publication, versus Co-PDF enzyme
0.00042
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.1
naphthalen-1-yl[[3-(trifluoromethyl)benzyl]amino]acetic acid
Staphylococcus aureus
pH and temperature not specified in the publication
0.07
p-chloromercuribenzoate
Escherichia coli
-
potent inhibitor, IC50: 0.07 mM
0.0000014 - 0.0000059
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
0.00000031 - 0.000003
propan-2-amine
0.00003
pseudopeptide metabolites
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.000030 mM
-
0.0088
purpurogallin
Homo sapiens
-
fluorescence polarization assay
0.0057
pyrogallin
Homo sapiens
-
fluorescence polarization assay
0.0089
quinalizarin
Homo sapiens
-
fluorescence polarization assay
0.00012
quinazoline hydroxamic acid
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.00012 mM
0.000072
SKI-AC-1
Homo sapiens
IC50: 0.000072 mM, actionin analog
0.000078
SKI-AC-10
Homo sapiens
IC50: 0.000078 mM, actionin analog
0.000076
SKI-AC-11101
Homo sapiens
IC50: 0.000076 mM, actionin analog
-
0.00006
SKI-AC-111101
Homo sapiens
IC50: 0.0000600 mM, actionin analog
0.000427
SKI-AC-111110
Homo sapiens
IC50: 0.000427 mM, actionin analog
-
0.000069
SKI-AC-111111
Homo sapiens
IC50: 0.000069 mM, actionin analog
0.000234
SKI-AC-111112
Homo sapiens
IC50: 0.000234 mM, actionin analog
-
0.000177
SKI-AC-111113
Homo sapiens
IC50: 0.000177 mM, actionin analog
-
0.0003
SKI-AC-111114
Homo sapiens
IC50: 0.000300 mM, actionin analog
-
0.000365
SKI-AC-11112
Homo sapiens
IC50: 0.000365 mM, actionin analog
-
0.0005
SKI-AC-11113
Homo sapiens
IC50: 0.000500 mM, actionin analog
-
0.000276
SKI-AC-11114
Homo sapiens
IC50: 0.000276 mM, actionin analog
-
0.000473
SKI-AC-11115
Homo sapiens
IC50: 0.000473 mM, actionin analog
-
0.000335
SKI-AC-11116
Homo sapiens
IC50: 0.000335 mM, actionin analog
-
0.000086
SKI-AC-11117
Homo sapiens
IC50: 0.000086 mM, actionin analog
0.000115
SKI-AC-11118
Homo sapiens
IC50: 0.000115 mM, actionin analog
0.000134
SKI-AC-11119
Homo sapiens
IC50: 0.000134 mM, actionin analog
-
0.000522
SKI-AC-11128
Homo sapiens
IC50: 0.000522 mM, actionin analog
-
0.0005
SKI-AC-11138
Homo sapiens
IC50: 0.000500 mM, actionin analog
-
0.00006
SKI-AC-11148
Homo sapiens
IC50: 0.0000600 mM, actionin analog
-
0.0005
SKI-AC-11158
Homo sapiens
IC50: 0.000500 mM, actionin analog
-
0.000192
SKI-AC-11168
Homo sapiens
IC50: 0.000192 mM, actionin analog
-
0.0002
SKI-AC-11178
Homo sapiens
IC50: 0.000200 mM, actionin analog
-
0.00012
SKI-AC-11188
Homo sapiens
IC50: 0.000120 mM, actionin analog
0.00009
SKI-AC-11198
Homo sapiens
IC50: 0.000090 mM, actionin analog
0.0005
SKI-AC-3
Homo sapiens
IC50: 0.000500 mM, actionin analog
-
0.0004
SKI-AC-5, SKI-AC-51121
Homo sapiens
IC50: 0.000400 mM, actionin analog
-
0.0004
SKI-AC-51121
Homo sapiens
-
IC50: 0.000400 mM, actionin analog
-
0.000097
SKI-AC-6
Homo sapiens
IC50: 0.000097 mM, actionin analog
0.000093
SKI-AC-8
Homo sapiens
IC50: 0.000093 mM, actionin analog
0.000151
SKI-AC-9
Homo sapiens
IC50: 0.000151 mM, actionin analog
-
0.000404
SKI-AC-I-18
Homo sapiens
IC50: 0.000404 mM, actionin analog
-
0.000239
SKI-AC-I-19
Homo sapiens
IC50: 0.000239 mM, actionin analog
-
0.0061
theaflavin
Homo sapiens
-
fluorescence polarization assay
0.0071
theaflavin monogallate
Homo sapiens
-
fluorescence polarization assay
0.000019
thio peptide
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.000019 mM, thiol chelating group combined with the best substrate motif
-
0.0025
thiol peptide
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.0025 mM, designed based on the best substrate identified
-
0.5
Thiophenol
Escherichia coli
-
IC50: 0.5 mM
0.043
thiram
Homo sapiens
-
fluorescamine assay
0.001
thyropropic acid derivatives
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.001 mM
-
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
0.000023
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.00003
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000006
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000007
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000077
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000017
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00002
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.0003
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000007
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000012
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000119
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.00001
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00001
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.0000035
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000004
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000058
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000016
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000025
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00055
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000011
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000078
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.0005
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000014
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000025
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000909
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000027
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000067
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.00046
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000128
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000215
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.006
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.0000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000018
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000015
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000005
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000008
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000004
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000007
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000012
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000023
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000055
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000054
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000022
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000077
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000044
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000002
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000049
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000008
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000019
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000045
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000046
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000021
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000061
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000021
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00002
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000011
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000038
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000088
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000077
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000032
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000069
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000019
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000001
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000041
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000026
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000014
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000031
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000048
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000002
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000047
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000066
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000031
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000044
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000015
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000013
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000043
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000041
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000014
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000061
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000035
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000014
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000059
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000037
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000014
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000047
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000035
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000017
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000044
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000008
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Escherichia coli
pH and temperature not specified in the publication
0.000017
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00011
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.0004
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.00036
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.00048
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000703
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000037
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000063
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.00013
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Escherichia coli
pH and temperature not specified in the publication
0.00036
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.00000012
2-phenylethanamine
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000086
2-phenylethanamine
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000036
2-phenylethanamine
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00011
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00015
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.000251
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000075
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.000211
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.0082
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.00002
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.00002
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.00065
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.0008
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0023
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.0000003
actinonin
Haemophilus influenzae
-
IC50 against Escherichia coli peptide deformylase: 0.0000003 mM
0.000003
actinonin
Streptococcus agalactiae
pH 7.5, 37°C, recombinant enzyme
0.0000053
actinonin
Escherichia coli
pH 7.5, 37°C, recombinant enzyme
0.0000075
actinonin
Arabidopsis thaliana
pH 7.5, 37°C, recombinant enzyme
0.000043
actinonin
Homo sapiens
-
competitive, IC50: 43 nM
0.00012
actinonin
Mycobacterium tuberculosis
-
wild type enzyme, in 20 mM phosphate buffer, pH 7.4, temperature not specified in the publication
0.00017
actinonin
Helicobacter pylori
-
pH and temperature not specified in the publication
0.0008
actinonin
Mycobacterium tuberculosis
-
mutant enzyme G151D, in 20 mM phosphate buffer, pH 7.4, temperature not specified in the publication
0.0055
actinonin
Homo sapiens
-
fluorescence polarization assay
0.026
calpeptin
Escherichia coli
pH and temperature not specified in the publication, versus Fe-PDF enzyme
0.0556
calpeptin
Bacillus subtilis
pH and temperature not specified in the publication, versus Fe-PDF enzyme
0.000045
H2O2
Salmonella enterica subsp. enterica serovar Typhimurium
pH 7.0, 30°C, recombinant wild-type enzyme
0.000049
H2O2
Salmonella enterica subsp. enterica serovar Typhimurium
pH 7.0, 30°C, recombinant enzyme mutant C130S
0.00015
H2O2
Salmonella enterica subsp. enterica serovar Typhimurium
pH 7.0, 30°C, recombinant enzyme mutant V63C
0.00016
H2O2
Salmonella enterica subsp. enterica serovar Typhimurium
pH 7.0, 30°C, recombinant enzyme mutant C130M
0.00144
H2O2
Salmonella enterica subsp. enterica serovar Typhimurium
pH 7.0, 30°C, recombinant enzyme mutant C130M/V63C
0.06
H2O2
Mycobacterium tuberculosis
pH 7.0, 30°C, recombinant enzyme mutant M145C
0.07
H2O2
Mycobacterium tuberculosis
pH 7.0, 30°C, recombinant enzyme mutant M145S
0.5
H2O2
Mycobacterium tuberculosis
pH 7.0, 30°C, recombinant enzyme mutant C58S
13.6
H2O2
Mycobacterium tuberculosis
pH 7.0, 30°C, recombinant enzyme mutant C59C
16.1
H2O2
Mycobacterium tuberculosis
pH 7.0, 30°C, recombinant wild-type enzyme
0.00000019
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000017
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000065
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000003
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000009
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000018
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000007
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000005
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000009
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000002
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000093
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000004
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000005
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000037
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000052
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000001
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000052
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000002
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000043
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000025
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000061
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000052
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000032
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000034
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000022
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000012
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000024
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000004
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000012
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000016
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000028
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000038
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000052
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000091
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000022
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000048
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00032
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
Haemophilus influenzae
-
i.e. SB 543668, IC50: 0.00032 mM
0.00115
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
Escherichia coli
-
i.e. SB 543668, IC50: 0.00115 mM
0.0022
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
Staphylococcus aureus
-
i.e. SB 543668, IC50: 0.0022 mM
0.00015
N-formyl-N-hydroxy-3-phenylpropylamine
Haemophilus influenzae
-
i.e. SB 485345, IC50: 0.00015 mM
0.00016
N-formyl-N-hydroxy-3-phenylpropylamine
Escherichia coli
-
i.e. SB 485345, IC50: 0.00016 mM
0.00025
N-formyl-N-hydroxy-3-phenylpropylamine
Staphylococcus aureus
-
i.e. SB 485345, IC50: 0.00025 mM
0.000005
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
Staphylococcus aureus
pH and temperature not specified in the publication
0.00031
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
Escherichia coli
pH and temperature not specified in the publication
0.0029
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
Escherichia coli
-
IC50: 0.0029 mM
0.00104
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
Haemophilus influenzae
-
i.e. SB 505684, IC50: 0.00104 mM
0.00109
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
Staphylococcus aureus
-
i.e. SB 505684, IC50: 0.00109 mM
0.0028
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
Escherichia coli
-
i.e. SB 505684, IC50: 0.0028 mM
0.00000038
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000023
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000007
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000072
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000033
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000063
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000051
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000024
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000058
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000003
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000015
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000023
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000014
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000027
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000059
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.00000031
propan-2-amine
Streptococcus pneumoniae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.0000016
propan-2-amine
Staphylococcus aureus
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
0.000003
propan-2-amine
Haemophilus influenzae
-
in 50 mM potassium phosphate (pH 7.6), at 25°C
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus aureus
-
6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
larger than 6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus aureus
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus aureus
-
0.78 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus enteridis
-
0.78 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus enteridis
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.78 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus aureus
-
0.78 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
0.049 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Streptococcus pneumoniae
-
3.13 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus aureus
-
larger than 6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus epidermidis
-
larger than 6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus enteridis
-
larger than 6.25 microg/ml
additional information
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
LBM-415
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
LBM-415
Staphylococcus aureus
-
0.39 microg/ml
additional information
LBM-415
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
LBM-415
Staphylococcus non-hemolyticus
-
0.78 microg/ml
additional information
LBM-415
Staphylococcus enteridis
-
3.13 microg/ml
additional information
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.39 microg/ml
additional information
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
6.25 microg/ml
additional information
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.195 microg/ml
additional information
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.195 microg/ml
additional information
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.195 microg/ml
additional information
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.195 microg/ml
additional information
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
0.195 microg/ml
additional information
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
3.13 microg/ml
additional information
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.39 microg/ml
additional information
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
1.56 microg/ml
additional information
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.195 microg/ml
additional information
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.39 microg/ml
additional information
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
3.13 microg/ml
additional information
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
3.13 microg/ml
additional information
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.78 microg/ml
additional information
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
3.13 microg/ml
additional information
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.049 microg/ml
additional information
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
0.049 microg/ml
additional information
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.195 microg/ml
additional information
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.39 microg/ml
additional information
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
0.39 microg/ml
additional information
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.39 microg/ml
additional information
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
0.78 microg/ml
additional information
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.78 microg/ml
additional information
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.39 microg/ml
additional information
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
3.13 microg/ml
additional information
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
larger than 6.25 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.098 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.39 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
1.56 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
1.56 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
3.13 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Streptococcus pneumoniae
-
0.195 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus epidermidis
-
0.78 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus aureus
-
3.13 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus enteridis
-
3.13 microg/ml
additional information
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
Staphylococcus non-hemolyticus
-
6.25 microg/ml
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.